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by 
 
CORRIE PURSER 
 
Under the Direction of Jenny J. Yang PhD 
 
ABSTRACT 
Protein based contrast agents (ProCAs) developed by the Yang lab exhibit unique 
capabilities in enabling magnetic resonance imaging (MRI) with significantly improved 
sensitivity and targeting capabilities by utilizing biomarkers which can target various carcinomas 
in animals.  Further clinical in vivo human applications require modifications of these designed 
contrast agents to further improve organ and tissue biodistribution, biomarker and cell targeting 
capabilities, and reduction of immunogenicity.  The aim of this thesis is to develop a novel 
protein modification on ProCA by glycosylation to improve liver distribution by targeting liver 
receptor, asialoglycoprotein receptor (ASGPR).  Rat and humanized first generation and 
humanized third generation ProCA were expressed and purified using either glutathione s-
transferase (GST) tagged or taggless methods.  Rat ProCA1, rProCA1, was then used to optimize 
glycan modification with glycosylation achieved at the highest level using a 100:1 molar ratio 
and three lysine residues.  Similar to non-modified rProCA1 and PEGylated rProCA1, metal 
binding affinity of gadolinium for glycan modified rProCA1, Glyco-rProCA1, was found to be 
9.49 x 10-12 M, and relaxivity was found to be greater than clinically available contrast agents 
ii 
with 34.08 and 42.67 mM-1s-1 for r1 and r2 respectively.  Glycosylation of rProCA1 has 
significantly increased human serum stability, and we have achieved significant liver MRI 
enhancement via tail vein injection due to high ASGPR expression in the liver altering 
biodistribution of glycan modified ProCA, and we have also imaged uptake in the secretory 
glands.  These biodistribution changes were noted by immunohistochemistry (IHC) staining 
which was found to stain liver sinusoid with spaces in between.  The distribution to the liver was 
further confirmed via inductively coupled plasma optical emission spectrometry (ICP-OES) 
which shows Glyco-rProCA1 has significant uptake of gadolinium in the liver tissue.  This study 
represents the first achievement of in vivo liver imaging by glycosylation using a lactose 
targeting moiety covalently bonded to protein contrast agents for MRI showing promise for 
future more specific targeting or whole body imaging capabilities. 
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1 INTRODUCTION 
1.1 Cancer 
Cancer has been ascertained as a leading cause of morbidity and mortality among 
individuals worldwide.  It occurs in the body when cells grow uncontrollably and no longer die.  
In regular cells a programmed cell death called apoptosis will occur before a neoplasm can be 
formed; however, in carcinoma cells, this programmable cell death is broken and invasive, and 
metastatic tumors can form.  Metastatic tumors are cancer cells that have spread throughout the 
body using the bloodstream making detection even more difficult and potentially will lead to 
death [1].   These cancer cells can interfere with normal functioning cells by up taking nutrients 
and resources by invading into the normal cells and tissues; this development is called 
metastasis.   
Half a million deaths due to cancer were projected by the American Cancer Society for 
2014, with the digestive and respiratory system being the biggest categories accounting for the 
deaths [2].  One major reason for such a large death rate is a lack of early and specific detection 
and diagnosis of these metastatic carcinomas.  Early detection and specific tumor diagnosis using 
noninvasive imaging for diagnosis are key avenues to explore in order for the decline of cancer 
mortality to continue in a downward trend as shown in Figure 1.1 [3].  This pattern in the United 
States can be contributed to improvements in cancer prevention, control, and improvements in 
medical practices.  The trend seen specifically reflects a rate decline in men, but the rate for 
women has remained steady.  This decrease in mortality in men is recognized as a decline in 
prostate, lung, and colorectal cancer [3].  The prostate cancer rate decrease is due to discovery of 
prostate-specific antigen, PSA, biomarker and utilization of PSA in screening patients for 
detection of prostate cancer.  It is important to develop personalized therapy options for patients 
2 
to specifically and quantitatively treat the 1.7 million patients that suffer from other cancers in 
the United States described in detail in Figure 1.2 [4].  Imaging methodologies for disease 
diagnosis can be used to early detect and monitor tumor cell growth and metastasis in a 
noninvasive way providing insight into effective treatment options for individual patients 
allowing the cancer to be quickly eliminated in the most efficient manner. 
 
 
Figure 1.1 Cancer mortality incidence rate ratios from 1999-2011 [3].  
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  Figure 1.2 Cases of cancer in the United States in 2015.  Adapted from reference with permission requested [4].  
1.2 Biomarkers in Cancer 
Is there a molecular target relevant to the disease of interest?  The understanding of the 
disease in this question when referred to cancer depends upon scientific understanding of 
biomarkers and how they play a role in cancer progression and detection.  Cancer cells are 
known to over express particular cell receptors when compared to normal cells.  Specific cancers 
will have corresponding specific receptors or biomarkers that can be used to detect the growth of 
a tumor quantitatively.  A biomarker indicates a change in expression or state that correlates with 
the risk or progression of a disease.  Biomarkers can be specific cells, molecules, genes, gene 
products, enzymes, or hormones.  Some commonly known biomarkers are listed in Table 1.1.  
4 
Most ideal targets for tumors will only be present in tumor cells and are easy to recognize by 
targeting reagents in blood circulation [5]. 
 
Table 1.1 Some biomarkers recognized by the FDA [6]. 
 
 
 
Lectin and glycan biomarkers to detect carcinoma have recently emerged for a wide 
range of disease states.  Some are already approved by the US Food and Drug Administration 
[7].  Irregular glycosylation has been reported to be related in various human diseases due to 
alterations in biological functions including signaling, protein folding, and trafficking.  The 
expression and biodistribution of lectins/glycans in different organs regulate their cellular 
functions in both physiological and pathological conditions.  Lectins and glycans are important 
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biomarkers for disease diagnosis, progression, and drug treatment.  Lewis Y (LeY), sialyl 
carbohydrates (SLex, and SleA), lectins, such as asialoglycoprotein receptor (ASGPR), and 
galectins are correlated with the presence, stage, and metastatic potentials of various types of 
cancers and other diseases [8, 9]. 
Biomarkers like glycans are created by mucins, glycoproteins in the mucus, due to the loss 
of normal topology and polarization of epithelial tissue in cancer results in secretion into the 
bloodstream [7].  Tumor cells invading the tissues and bloodstream also present these mucins on 
their cell surface.  When this phenomenon occurs these biomarkers can be used to evaluate the 
growth of a carcinoma in vivo.  Continuous research into cancer biomarkers provides an avenue 
for evaluation and diagnosis of disease development and detection.  There are many biomarkers 
that have been well established and associated with specific cancers.  Coupling the information 
provided from biomarker discovery with imaging techniques for disease diagnosis provides an 
exciting avenue to evaluate the mechanism of cancer progression and can provide answers for 
many questions that clinicians face when diagnosing patients.  We have to probe further into this 
to see if there is an affinity ligand that can be used to target disease biomarkers like lectins and 
detect it using imaging methodologies for disease diagnosis. 
1.3 Imaging Methodologies used for Disease Diagnosis 
Imaging soft tissue in vivo for early disease detection and diagnosis is now attainable due 
to several medical imaging modalities that are currently being used to clinically diagnose 
patients by differentiating between healthy and diseased tissue.  Major imaging modalities used 
for diagnosis include: x-ray, computed tomography (CT), positron emission tomography (PET), 
PET-CT, single-photon emission computerized tomography (SPECT), optical imaging, 
ultrasound, magnetic resonance spectroscopy (MRS), and MRI.  The utilization of these 
6 
techniques allows medical professionals to tailor therapy to patients in a non-invasive manner 
that has not been possible in the past.  Molecular imaging also holds potential in optimizing the 
development of anticancer pharmaceuticals to expedite approval of cytotoxic anticancer 
therapies [10].  Implementing molecular imaging provides an option that will avoid harsh 
biopsies and surgical procedures patients would need to undergo in order to be diagnosed.  
Medical imaging techniques have the potential to provide a molecular profile of tumors during 
diagnosis and during therapy application that would allow quantification of the diseased tissue in 
vivo [11].  The various imaging modalities have advantages and disadvantages for obtaining 
physiological and functional information explained in detail in Figure 1.3 [11].  Among the 
imaging techniques MRI is assessed as the most advantageous imaging modality to aid in the 
detection and quantification of various tumors for cancer diagnosis using protein based contrast 
agents. 
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Figure 1.3 Comparison of various medical imaging methodologies [11, 12]. 
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1.3.1 X-Ray 
X-ray is a form of electromagnetic radiation that creates an image by passing x-rays 
through a patient and the detector on the other side of the patient images the rays produced.  It is 
an imaging modality usually used for imaging bones and other organs.  One issue with 
implementing this technique is exposure of the patient to gamma-emitting radioisotopes.  The 
introduction of x-ray digital subtraction angiography, DSA, around 1980 provided a way for x-
ray to be utilized as an imaging methodology to detect disease in vivo by using contrast agents.  
Contrast agents used in x-ray imaging include gold nanoparticles, AuNPs.  Gold nanoparticles 
have been used to monitor and detect tumor cells during necrosis and proliferation in mice [13].  
AuNPs are limited by uptake in individual cells because this will limit the image contrast and 
AuNPs can interfere with cell proliferation. 
X-Ray as a form of molecular imaging has been greatly improved on by application of an 
x-ray imaging technique called spatial frequency heterodyne imaging, SFHI.  The currently 
offered clinical imaging techniques suggest that the sensitivity of SFHI is comparative to MRI; 
however SFHI delivers harmful ionizing radiation to patients being imaged [14].  This technique 
uses x-rays scattering off a sample to create an image.  Contrast agents such as gold and iron 
oxide nanoparticles have been used to enhance sensitivity when using SFHI.  Hepatocellular 
Carcinoma, HCC, has been imaged using SFHI by utilizing AuNPs.  Protein based 
“nanobubbles” are newly developed contrast agents for SFHI that has shown a comparable 
contrast to AuNPs.  These nanobubbles are comprised of a “protein cage” filled with 
perfluoropropane gas encapsulated by apoferritin proteins and virus-like particle capsids.  
Modification to these nanobubbles using targeting and therapeutic agents for delivery can also be 
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combined with the molecular imaging functionality; however, this is limited due to exposure of 
patients to gamma-emitting radioisotopes that are required for imaging in vivo [15]. 
1.3.2 Computed Tomography  
Computed tomography is an x-ray based imaging technique used to create a succession of 
scans that images slices in areas of the body and can be used to create either 2-D or 3-D images.  
CT is clinically available, efficient, and cost effective and has potential to be used as a molecular 
imaging modality.  CT also is desirable due to its unlimited depth penetration, and high spatial 
resolution capabilities.  Whole-body imaging that provides anatomical information is possible 
with a short acquisition time making the clinical application of this imaging modality convenient 
for use in the medical field.  These advantages are not applicable without consideration of the 
disadvantages such as the risk of irradiation exposure to patients.  This imaging modality also 
has poor soft tissue contrast and as a result is mostly only used to provide anatomical and 
functional information and least used for molecular imaging when contrast agents are not 
applied. 
Current CT contrast agents are iodine containing molecules and these contrast agents are 
effective at absorbing x-rays; however they are rapidly cleared by the kidneys limiting the 
imaging.  AuNPs used as contrast agents for CT hold potential due to the ability to determine 
differences between various tissues due to x-ray attenuation.  Popovtzer et al. demonstrated the 
ability to target and identify via CT squamous cell carcinoma using immuno-targeted AuNPs.  
An x-ray signal attenuation was seen as the AuNPs gathered on the targeted cancer cells that 
could be determined from healthy or untargeted cancer cells; however these targeted contrast 
agents are also limited due to the gamma-emitting radioisotopes that are required for imaging in 
vivo [16].  
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1.3.3 Positron Emission Tomography  
PET is an imaging modality in nuclear medicine that has been used in clinical imaging 
mostly for brain imaging and studying metabolism in tumors.  PET detects the radiation emitted 
by radiotracers injected into patients. These studies require radioisotopes with a long enough 
half-life for biodistribution to be readily available, however; one major disadvantage to using 
PET as a clinical tool is the need to find radioisotopes with relatively short half-lives that will 
minimize radiation to potential patients.  Fluorine-18 is a positron emitter currently used in the 
agent flurodeoxyglucose, FDG, which is an F-18 tagged molecule that is metabolized by tumors.   
While FDG works well in full body imaging to evaluate metastatic cancer, it is not 
specific and exposes patients to harmful radiation.  PET does provide quantitative information 
with unlimited depth penetration and whole-body imaging capabilities; however, PET also 
carries the disadvantage of low spatial resolution due to scattered radiation and random events 
created during imaging.  PET is also expensive, low in spatial resolution (1-2 mm; 4-8 mm3), and 
requires a long acquisition time (minutes to hours) to create images and gather information [17].   
1.3.4 Single Photon Emission Computed Tomography  
SPECT is also a clinical imaging modality of nuclear medicine that is used mostly in the 
field of cardiology for monitoring heart disease by using different detectors than PET to create 
images [18].  Similar to PET imaging, SPECT is also used for monitoring increased glucose 
uptake in tumor cells using radio labeled molecules like FDG.  The need to utilize FDG radio 
labeled agent is limited by the need to generate FDG using a nearby cyclotron at high cost [19].  
Lin et al. established a technetium mebrofenin, 99mTc, complex that serves as a potential 
radiopharmaceutical probe that is affordable and readily available.  The probe was found to be 
transported via a glucose transporter; however, the liver and kidney uptake was found to be too 
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large when administered to rabbit models to specifically assign tumors in the liver and kidney.  
SPECT is limited by high cost to generate a radiopharmaceutical that is not specific to diagnose 
patients and monitor patients during treatment with a personal therapy approach at the risk of 
harsh radiation.  SPECT also holds a disadvantage of low spatial resolution. 
1.3.5 PET/CT and SPECT/CT Dual Imaging 
Although 18F-FDG PET imaging has low resolution, this can be made up for by using a 
dual imaging modality that implements CT and a different radiotracer that increases resolution 
by integrating the anatomical information by using CT [20].  SPET/CT has high sensitivity and 
depth penetration, however they both use harmful irradiation to create images in vivo.  A system 
of contrast using radiotracer 18F-FDG PET and the other radiotracer, 11C-acetate, reflects lipid 
metabolism [21].  While these imaging techniques combined provide insight about tumor 
development, the need for exposure to harsh radiation is a disadvantage that should be taken into 
consideration.  
1.3.6 Ultrasound 
Ultrasound emits high frequency sound pulses into a patient’s body that will be 
transmitted back when they come into contact with tissues, fluid, and bones.  These reflected 
waves are used to create an image.  Ultrasound is advantageous in high spatial resolution in the 
range of 50–500 µm and provides anatomical information with molecular information that 
clinicians can utilize in diagnosing patients.  Ultrasound has a disadvantage when it comes to 
tissue penetration; however, it does have high temporal resolution.  There is a trade off when it 
comes to tissue penetration and spatial resolution according to Gharib et al [12].  Cirrhosis of the 
liver in cases of patients with hepatocellular carcinoma, HCC, causes an issue in imaging of 
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HCC tumors using ultrasound because cirrhosis causes changes to the texture of the liver [22].  
While this disadvantage in tissue penetration and spatial resolution causes an issue, another 
problem with using this technique is the inability to perform whole-body imaging; however, 
patients are not at risk to ionizing radiation and acquisition time for creating images is short.  
Characterization of focal liver lesions is possible using microbubble contrast agents as well as 
echocardiography. 
1.3.7 Optical Imaging 
Optical imaging is a mode of detecting photons when they interact with tissues in vivo.  
One disadvantage to using optical imaging as an imaging modality is scattering of light in tissue 
as evaluated by Luker et al [23].  Molecules in the body absorb light and reduce signals created 
by optical imaging probes and instruments.  Near-infrared fluorescence, NIRF, is one technique 
that detects photons emitted on the far red range.  This technique allows for deep tissue 
penetration up to 10 cm.  Optical Imaging also holds a disadvantage of low spatial resolution in 
the 1-2 mm range according to Gharib et al [12].   
Fluorescent imaging is also an optical molecular imaging technique that can be used as a 
guided surgery when removing tumors in patients.  Fluorescence imaging uses fluorochromes to 
augment the visualization of the tumor to the operating surgeon beyond a white-light reflectance 
this allows for tumor removal to be improved and recovery to be continuous.  This type of 
optical imaging improves relative sensitivity, and resolution in the submillimeter range when 
used endoscopically [20].  A highly sensitive and target-specific fluorescent probe must be 
available for clinical use to utilize this technique [24]. 
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1.3.8 Magnetic Resonance Spectroscopy 
MRS is a radiological technique that can provide spatial and quantifiable metabolic 
information of tumors and normal tissue.  The information is observed as a spectrum of 
resonance peaks along the x-axis as parts per million, ppm, and the amplitude of resonances is 
measured on the y-axis at a random scale and can provide biochemical information that can aid 
in the detection of tumors.  Various metabolic markers in the brain can be detected and 
information can then be extrapolated about the tissue.  For example, creatinine, Cr, is a marker 
for cell energy metabolism.  Decrease in Cr has been associated with tissue death [25].     
1.3.9 Applications of MRI as a Diagnostic Tool 
Magnetic resonance imaging has a distinctive capability for gathering 3-dimensional 
images of living organisms with advantageous high spatial resolution and without limitations in 
the depth of tissue or organs, and these images are captured without the harmful ionized radiation 
that can occur using other imaging methodologies [26].  MRI is a leading diagnostic technique in 
both the preclinical and clinical arenas that is developed from the basic elements of nuclear 
magnetic resonance, NMR [27].  This technique will give important biological, chemical, and 
functional information about an organism in a non-invasive manner.   
Magnetic resonance imaging, MRI, is a non-invasive technique used in clinical fields for 
imaging tissues in vivo and offers images with high resolution, three-dimensional pictures that 
can provide a differentiation between diseased and healthy tissue by using contrast agents, CA.  
Three-dimensional images of soft tissue can be observed by measuring the magnetic properties 
of hydrogen in water when it is acted on by a radiofrequencey, Rf, while inside a magnetic field, 
B0.  MRI measures the total angular momentum of the nucleus to create an image and it uses 
different variables to construct this image.  While spin density in MRI is used to measure the 
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proton density, flow and spectral shifts also contribute to constructing the images, and T1 and T2 
relaxation times are variables that help contribute to the contrast in imaging between diseased 
and non-diseased tissue [28].   
Images for MRI are created by relaxation rates of hydrogen nuclei single protons.  The 
protons in hydrogen atoms create multiple spin states in the form of magnetic and angular 
moment with a net spin of ±1/2, magnetic quantum number, and are unpaired producing 
magnetic properties due to vibrational and rotational motion.  This creates magnetization due to 
the odd number of protons in the nuclei.  These hydrogen nuclei are low in energy and have 
random alignment when outside of an external B0.  When a uniform external B0 is applied, the 
hydrogen atom nuclei will align parallel or anti-parallel in the B0 creating net magnetic moment, 
M.  When these spinning nuclei are introduced to the strong static magnetic field they will 
precess at the Larmor frequency, ω.  This frequency will depend on gyromatric ratio, γ; ratio of 
angular momentum, J; and the magnetic field, B0.  Larmor frequency is defined in Equation 1-1.    
࣓ = ࢽ࡮૙  Equation 1-1 
Hydrogen nuclei have the ability to absorb energy that is formed when a pulse of Rf 
electromagnetic radiation is applied in a perpendicular manner to the B0.  This causes the nuclei 
axis to tilt from the magnetic field as depicted in Figure 1.4 [29].  When Rf is removed, 
relaxation will occur which is the energy absorbed in the hydrogen nuclei decaying back to a low 
energy state.  This process is measured and a signal is produced as the nuclei orients back to its 
initial position in relation to the B0.  This signal produces an image that is recorded in MRI.  The 
time frame required for the nuclei to return to this orientation is related to the enhancement of the 
MRI images.  There are two relaxation methods that will occur concurrently depending on the 
axis of orientation.  The longitudinal or spin-lattice relaxation, r1, and transverse or spin-spin 
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relaxation, r2, will determine the contrast in the images created depending on the time to return to 
the original state.  The time it takes for the nuclei to realign back to its initial orientation in the 
magnetic field along ZY plane is called spin lattice or longitudinal time T1.  This is depicted in 
Figure 1.5 along with the dephasing of nuclei back along the XY plane creating a spin-spin 
relaxation time, T2.  Due to a large background signal created by water in the human body it is 
difficult differentiating between tissues of organs and soft tissue making sensitivity of this 
technique lower and requires clinicians to make use of contrast agents to increase sensitivity for 
determining diseased tissue and normal tissue. 
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Figure 1.4 Diagram illustration of nuclei under a magnetic field and the relaxation process.  Adapted from reference with permission [29].  
Original State Magne c Field Parallel or an parallel Spins aligned 
B0 
RF Pulse 
   B0 
17 
 
 
Figure 1.5 Diagram illustration demonstrating relaxation.  Adapted from reference with permission [30].  
 MRI provides an option for diagnostic high resolution imaging that is non-invasive without 
harmful radiation, and is consequently advantageous when compared with other imaging 
techniques.  MRI is a highly sensitive technique, when MRI contrast agents are utilized, that 
provides deep penetration in tissue, but one barrier preventing disease diagnosis using MRI is a 
lack of contrast agents that can provide high T1 and T2 relaxation times to image tissue.  In MRI 
the water molecules are providing the T1 and T2 relaxation and depending on the water content 
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in the tissue a contrasted image is produced.  ProCA have been designed to provide the needed 
T1 and T2 relaxation times that have been lacking to implement this technology in specifically 
targeting diseased tissue [26]. 
1.4 MRI Contrast Agents 
In order to overcome the low sensitivity of MRI, clinicians can utilize MRI contrast 
agents.  MRI contrast agents are divided into paramagnetic and super-paramagnetic magnetic 
nanoparticles which have unpaired electrons capable of being influenced by a magnetic field.  
Contrast agents increase the signal by shortening the relaxation time produced by the relaxation 
rate of water protons.  Paramagnetic MRI contrast agents contain lanthanide elements such as 
gadolinium.  Super-paramagnetic magnetic nanoparticles contain iron oxides that manipulate T2 
relaxation [31].  Gadolinium bases contrast agents contain a binding pocket that chelates 
gadolinium which is a trivalent lanthanide metal ion with seven unpaired electrons, high 
magnetic moments, and long electronic relaxation times due to its symmetric s-state making it 
the most frequently used metal ion for MRI.  Chemical instability of the chelate can lead to 
exchanges with other metal ions (zinc, calcium, etc.) and have biological consequences. 
1.4.1 Characteristics of Clinically Available Contrast Agents 
Magnetic resonance imaging is one noninvasive technique that is used to detect and study 
diseased tissue and can be helpful for cancer diagnostics. One major challenge in implementing 
this technique is the current clinically used MRI contrast agents exhibiting low relaxivity, 
specificity, dose efficiency and sensitivity making it hard to image and differentiate between 
diseased and healthy organ tissue.  One way to overcome this issue is developing and designing a 
series of novel protein based contrast agents, ProCA, with improved relaxivity, sensitivity, lower 
toxicity, stability, and sensitivity.    
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Current clinically approved contrast agents have one Gd3+ molecule that is chelated into 
a small organic chelator such as diethylene triamine penta acetic acid (DTPA), or 
tetraazacyclododecane tetraacetic acid (DOTA) as depicted in Figure 1.6 [32].  Gadolinium 
based contrast agents that are currently available share characteristics of low relaxivity and high 
toxicity as shown in Table 1.2.  FDA approved contrast agents have relaxivities of 4 – 5 mM-1 s-1, 
but theoretically they are expected to have relaxivities of around 100 mM-1 s-1.  This issue can be 
contributed to their low water exchange and fast molecular rotation time, due to these reasons the 
possibility of achieving such a high relaxivity of 100 mM-1s-1 is hindered [33].  The FDA 
approved contrast agents have poor organ specificity and no targeting capability.  Injection of 
targeted protein based contrast agent can vastly improve diagnosis capabilities using MRI by 
increasing the image enhancement of the specified area, increasing relaxivity, rotational 
correlation time, and having better retention. 
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Figure 1.6 Commercially available, clinical used and FDA approved MRI contrast agents.  Adapted with permission requested from reference [32]. 
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Table 1.2 List of contrast agents with restrictions and dosage approval in the world [34]. 
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1.4.2 Toxicity of Clinically Available Contrast Agents 
Continuous injection of a contrast agent with low circulation time or high clearance with 
small molecular weight increases likelihood of developing a metal toxicity related disease such 
as nephrogenic systemic fibrosis, NSF.  NSF can be caused by free gadolinium released in the 
body.  Symptoms of NSF include advancing and severe fibrosis of the skin and other systemic 
organs that leads to substantial disability especially in those diagnosed with kidney disease and 
recent exposure to gadolinium based contrast agents as depicted in Figure 1.7 [35].  Current 
clinically approved contrast agents have one Gd3+ that is incorporated into a small organic 
chelator such as diethylene triamine penta acetic acid, DTPA, or tetraazacyclododecane 
tetraacetic acid, DOTA. High concentrations of free gadolinium, lower blood retention and 
decreased in vivo relaxivities may increase the risk of causing NSF. Weak binding between Gd3+ 
and its chelators leads to accumulation of free gadolinium and free chelators in the kidney causes 
lack of proper excretion out the body, and inevitably can cause renal failure. 
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Figure 1.7 Nephrogenic systemic fibrosis on the skin [35].  
 
1.4.3 Criteria for Designing ProCA 
Development of ProCA began in order to develop a clinically applicable protein-based 
MRI contrast agent.  Criteria determined by the limitations of the current clinically available 
contrast agents include: high stability and solubility, appropriate molecular weight, tolerance to 
mutations, high relaxivity, strong Gd3+ stability and metal selectivity over physiological metals, 
no toxicity, and the production must be cost and time efficient.  A high-quality contrast agent 
will be stable in vivo with a longer retention time to reduce dosage frequency in order to avoid 
gadolinium toxicity.  The criteria of an increased relaxivity also provides an avenue to avoid high 
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dosages of contrast agent in order to provide a high quality image.  The high affinity for 
gadolinium over metal ions such as zinc, calcium, and magnesium prevents free gadolinium from 
being released into the blood stream.   
As discussed previously, development of a contrast agent with a strong gadolinium 
binding affinity is important criteria to address in the development of ProCA.  This is one 
advantage ProCA provides due to the metal binding pocket or pockets created by various 
computational and protein engineering tactics.  The required mutations to create ProCA metal 
binding pockets must not modify the protein folding and tertiary structure of the protein.  A third 
advantage of ProCA is contributed to the size of the contrast agent (10-12 kDa) that provides 
good circulation time with easy penetration with an avenue of excretion out either the kidneys or 
liver.  These proteins can also be modified or conjugated with targeting moieties to biomarkers 
that provide specific and quantifiable information on disease progression. 
ProCA, developed by protein engineering, binds gadolinium to altered scaffold proteins 
and increases the amount of bulk water in the surrounding area being imaged. Gd3+ interacts with 
the surrounding bulk water with one inner sphere water, three-second sphere water molecules 
and several outer sphere water molecules, depicted in Figure 1.8, left, [33].  Gadolinium will 
interact with the surrounding water molecules when it is bound to the scaffold protein in the 
metal binding pocket.  This interaction occurs with one inner water molecule and three second 
sphere water molecules, and it is also impacted by several outer sphere water molecules.  Protein 
modification with hydrophilic PEG or glycan reagent increases the tumbling or rotational 
correlation time, τr, which is dependent on the molecular size, and plays a major role in 
enhancement of relaxation properties, also shown in Figure 1.8, right, with a comparison to the 
relaxivity properties of clinically available MRI contrast agents.   
25 
 
Figure 1.8 Diagram of water exchange and the impact on relaxivity.  Adapted from reference with permission requested [33].  Left:  Gadolinium interacts with surrounding bulk water when bound to the scaffold protein metal binding pocket.  This interaction occurs in one inner sphere water molecule, three second sphere water molecules and several outer sphere water molecules. Conjugation with hydrophilic PEG or glycan reagent increases the tumbling or rotational correlation time, τr, which is dependent on the molecular size, and plays a major role in enhancement of relaxation properties. Right:  Graph depiction of the enhancement of relaxation properties based on the design of ProCA compared to clinically available contrast agents.   
1.4.4 Immunogenicity of ProCA 
ProCA are advantageous over small molecule contrast agents due to the biocompatibility 
of protein based therapeutic agents which make in vivo application viable because ProCA are 
biological molecules compared to small molecule gadolinium chelators; however, ProCA are 
limited due to immunogenicity effects.  The immune system identifies protein therapeutics by 
recognizing antigen features using B and T cells.  This interaction can lead to clinical 
immunogenicity.  Steps can be taken in the development of protein therapeutics to block this 
recognition and reduce the effects of immunogenicity [36].  Protein solubility is one important 
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characteristic needed to reduce immunogenicity of these types of therapeutics.  Reducing 
immunogenicity by replacing protein sequences from non-human sequences with human 
sequences is an approach that can be taken.  Removing antibody epitopes are another way to 
avoid immunogenicity effects.  This work focuses on reducing immunogenicity using a novel N-
glycosylation approach. 
1.4.5 Lysine PEGylation and Glycosylation Modification of ProCA 
Modification of therapeutic proteins using polyethylene glycol is a standard way to 
increase pharmacological effects.  Protein aggregates present in protein therapeutics can elicit an 
immune response by increasing uptake of the therapeutic agent by antigen presenting cells, 
APCs, and prolonged contact with T cells.  Protein solubility is important in developing a protein 
therapeutic to reduce immunogenicity.  In order to reduce protein aggregates by insoluble protein 
therapeutics PEGylation will help improve solubility.  The addition of PEG also creates a block 
for antibodies binding antigen sites on protein therapeutics.  Lysine modification using PEG has 
previously been covalently coupled with ProCA in order to address these issues with protein 
therapeutics, as well as, to add the benefit of increasing hydrophilic properties of ProCA which 
demonstrated significant improvement in the in vivo MR imaging and r1and r2 relaxivities along 
with improved biocompatibility properties including dose efficiency, solubility and blood 
retention and decreased immunogenicity [37].  Other benefits of PEGylation include increased 
circulatory half-life and decreased degradation from metabolic enzymes; however, PEG is not 
biodegradable [38].   
Site-selective glycosylation of hemoglobin with variously sized carbohydrates was 
performed by Styslinger et al. as a potential alternative for PEGylation [39].  The glycosylation 
of hemoglobin was then investigated further to determine the change in biophysical properties.  
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It was found, similarly to PEGylation, glycosylation provides a large hydration shell capable of 
protecting proteins from proteolysis and glycosylation has the added benefit of being able to 
stabilize the protein by forming hydrogen bonds with a protein’s amino acid residues [38].  
These added benefits along the biodegradability of glycosylation makes this method an attractive 
alternative to decreasing immunogenicity and increasing dose efficiency, circulation half-life, 
and solubility of ProCA; however, glycosylation also plays an important role in the discovery of 
biomarkers for carcinoma which is discussed in further detail in Section 1.6.  The lysine N-
glycosylation of first generation ProCA is the focus of this study; however, several generations 
of ProCA have been designed. 
1.4.6 ProCA1 
Designed ProCA developed by Dr. Jenny Yang’s lab has proven characteristics that have 
been able to surpass the limitations mentioned above for clinically available MRI contrast agents.  
In order to achieve this, a scaffold protein that can tolerate mutations and keep a stable and 
ridged structure when injected in vivo [40].  Scaffold proteins for designed contrast agents are 
designed after analysis of calcium binding proteins.  A calcium binding pocket was created by 
several mutations in a non-calcium binding protein which demonstrated calcium binding over 
magnesium with dissociation constant of 50 μM that is very much similar to naturally existing 
extracellular calcium binding proteins [40].  This protein, Domain 1 of rat CD2, became the first 
generation de novo design of ProCA.  Several other generations of ProCA have been developed 
since this design, including the humanized variation of this contrast agent.   
Rat ProCA1, protein contrast agent generation one, consists of Domain 1 of rat CD2 
originated from cell adhesion 2, CD2, from the T-cell receptor in the immune response system.  
This protein maintains its original conformation with a β-sheet topology when tested with 
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varying pH and temperatures [41].  The Gd3+ binding pocket was made by mutating residues Asn 
15 to Glu, Leu 58 to Asp, and Lys 64 to Asp on this protein.  Oxygen from the side chains of Glu 
15, Glu 56, Asp 58, Asp 62 and Asp 64 work as a chelator and together from different regions of 
the protein sequence they form a binding pocket for gadolinium, depicted in Figure 1.9.  One 
coordination position on the gadolinium atom is kept open to allow for a fast water exchange rate 
with physiological water oxygen atoms filling this coordination point.  This figure also shows the 
pentagonal bipyramidal coordination of gadolinium bound to rProCA1 with the protein structure 
adapted from the RCSB protein data bank, PDB [42]. 
  
 
Figure 1.9 Coordination geometry of gadolinium bound in rProCA1.  
 Humanized ProCA1, similarly to rProCA1, is constructed from CD2 Domain 1 of human 
T-lymphocyte and was used as the scaffold protein to design hProCA1.  Humanization provides 
a pathway to avoid the immune response system.  Immunogenicity, as described in the section 
29 
above, 1.4.3, can be avoided by replacement of a murine protein therapeutic sequence to a 
human one.  This process is called humanization and immunogenicity can become a problem due 
to development of anti-murine antibody response in clinical used.  Humanization of protein 
therapeutics is an important step to take on the road to drug discovery.  We address this problem 
by using a protein sequence that is produced by the human body [43].  In order to engineer a 
humanized protein therapeutic, protein engineering as described previously must be implemented 
into a human protein sequence.  CD2 Domain 1 of human origin is used to develop a contrast 
agent modeled after the original rProCA1.  The first step in this development is to evaluate the 
similarities and differences in the wild type sequence of murine CD2 Domain 1 and human CD2 
Domain 1 depicted in Figure 1.10.  This figure shows the sequence alignment identities with a 
47% positive alignment with the wild type rProCA1 (top sequence) and wild type hProCA1 
(bottom sequence).  The low degree of sequence identity reveals a need to make novel mutations 
to the hProCA1 to provide protein stability.  Humanized ProCA1 was mutated at sites Asn 18 to 
Glu, Asp 20 to Asn, Leu 63 to Asp, Thr 75 to Asp, and Lys 66 to Asp.  Figure 1.11 shows a 
cartoon depiction of hProCA1 (middle) modeled from PDB file x-ray crystal structure, along 
with the other two contrast agents, rProCA1 (left) and hProCA32 (right), that will be discussed 
[44].  In this image, the red residues are mutated residues with residues that contribute to the 
binding pocket shown using the ball and stick model.  The yellow residues contribute to the 
binding pocket without mutation.  Rat and humanized ProCA1 show a cartoon depiction of 
gadolinium bound to the metal binding pocket, while hProCA32 depicts calcium bound with two 
metal binding pockets. 
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Figure 1.10 Protein sequence alignment of the wild type protein rat CD2 Domain 1 (top) and human CD2 Domain 1 (bottom) for humanization.  
 
 
Figure 1.11 Cartoon depiction of rProCA1, hProCA1, and hProCA32.  
1.4.7 ProCA32 
First generation ProCA demonstrated improved relaxivity, sensitivity, selectivity, stability 
and high targeting capability as compared to the commercially available contrast agents. 
Although ProCA1 demonstrates excellent r1 and r2 relaxivities it exhibits relatively weaker Gd3+ 
binding constants than the dissociation constant of the commercial contrast agent Gd-DTPA 
(1.86 × 10 -21 M), which is important for in vivo application as an MRI contrast agent to avoid 
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toxicity from free gadolinium.  In order to improve the thermostability during purification, a 
thermodynamically stable scaffold protein was selected, and modified at the metal binding sites.  
These metal binding sties created additional binding sites to optimize readout, this third 
generation series of ProCAs, ProCA3 was designed by Dr. Shenghui Xue.  A new scaffold 
protein parvalbumin was selected due to many advantages associated with its physical and 
functional properties.  Parvalbumin is small, rigid, and globular with a molecular weight of 11-
12 kDa.  It is a part of calcium binding protein family, consisting of two Ca2+ binding sites [45].  
Parvalbumin demonstrates a strong thermo-stability, high solubility, and resistance to protease 
cleavage and is tolerant to mutations. Keeping the above parameters in mind, different mutants 
of ProCA3, with parvalbumin as scaffold protein, were generated to engineer a stronger Gd3+ 
binding site.  
Wild type parvalbumin has two calcium binding sites that are EF hands, a helix-loop-helix 
motif found in calcium binding proteins.  EF hand Site I is formed by four carboxyl amino acid 
residue ligands (D52, D54, E50 and E63) and one non-charged oxygen ligand (S56) that directly 
interacts with calcium. EF hand Site II has carboxyl groups (D91, D93, D95 and E102) and uses 
G99 with a water ligand to hold Ca2+ in the binding pocket.  Calcium and lanthanide ion binding 
affinities can be selectively improved by introducing a negative charge in the binding pocket. 
Various mutations were performed and tested for its metal binding and relaxivity.  An increased 
metal selectivity for Ca2+ or lanthanides can be achieved by increasing the negative charge in the 
metal co-ordination shell [46].  To create a humanized contrast agent based on parvalbumin, 
mutations to Site I at Ser 56 to Asp and to Site II at Asp 101 to Glu was performed to increase 
the Gd3+ binding affinity.  Furthermore, an additional mutation Phe 103 to Trp, adjacent to the 
Site I binding pocket was made to enable fluorescence emission for protein detection.  Rat 
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ProCA32 demonstrated stable serum stability, has low toxicity and behaves as a ratiometric 
T1/T2 weighted contrast agent.  Humanized ProCA32 contrast agent is modeled by Chimera 
UCSF from an x-ray crystal structure PDB file above in Figure 1.11 (right) [47]. 
1.5 Targeting Biomarker Human Epidermal Growth Factor Receptor 2 Using an 
Affibody Grafted to Designed Contrast Agents  
Human epidermal growth factor receptors, EGFRs, are composed of four family 
members (EGFR/HER1, HER2/Neu, HER3 and HER4). They share similar structures with an 
extracellular ligand binding domain, a transmembrane domain, and a functional intracellular 
tyrosine kinase domain (except for HER3). Different from other three receptor family members, 
HER2/Neu does not have a natural ligand and its ECD domain is able to adopt an activated state 
by dimerizing with EGFR or HER3 (EGFR/HER2, HER2/HER3) creating a heterodimer, 
depicted in Figure 1.12 (right). HER2 is the preferred dimerization partner in the EGFR family. 
HER2/Neu and EGFR are also major prognosis biomarkers over-expressed in various types of 
cancer cells and tissue samples of cancer patients (shown in Figure 1.12, left) [48].  HER2 
expression, as described in Table 1.1, is also over expressed in the early stages of these cancers, 
which will be beneficial for early diagnosis of carcinoma described [49]. 
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Figure 1.12 HER2 expression level in cancer cells and signal transduction.  Adapted from reference with permission requested [50].   Various antibodies or other peptides have been developed to target to HER2 [51].  These 
structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and 
show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. 
By identify the binding patterns of Herceptin Fab domain and HER2 ECD, a basis of designing 
new targets for HER2 has been generated for diagnosis and therapeutic effects.  Using this 
information Dr. Jingjuan Qiao engineered an affibody, depicted in Figure 1.13 (bottom), into the 
C-terminal of the designed Gd3+-binding hProCA1 by a flexible linker. The affibody, ZEGFR:1907, 
was screened from an affibody library to bind the extracellular domain of EGFR with a Kd of 
43.6 nM [50].  This affibody was developed using many mutations, shown in Figure 1.13 (top), 
to find a high-affinity affibody for EGFR developed by phage display selections based on the 58 
amino acids in the Z domain of staphylococcal protein. 
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Figure 1.13 Sequence alignment of generational Z Domain affibody and modeled structure of hProCA1-affi.  Adapted from reference with permission requested [50].  
1.6 Targeting Lectin Biomarkers via Glycosylated Protein-Based MRI Contrast Agents 
1.6.1 Hepatocellular Carcinoma Lectin Biomarker Recognition 
The American Cancer Society calculates 24,550 people will die of liver cancer while 
35,660 new cases are diagnosed in 2015 [4].  Symptoms and signs of hepatocellular carcinoma, 
HCC, consist of abdominal pain, swelling and weakness, loss of appetite, jaundice, fever, or 
enlargement of liver.  These symptoms mainly arise in the later stages of cancer making early 
detection or screening imperative because the five-year survival rate for liver cancer is currently 
15% due to lack of early detection in the initial stages.  Early detection could vastly increase the 
five-year survival rate to 60-70% with liver transplant.  Treatment options for patients include 
liver resection or liver transplant depending on the level of cirrhosis in the liver.  Early detection 
is key for increasing disease-free survival rates for patients diagnosed with this disease.   
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ASGPR, is a protein expressed on mammalian hepatocytes.  ASGPR is a C-type lectin 
with the role to maintain glycoprotein stability in serum by binding and internalizing 
glycoproteins.  In order to perform this function ASGPR must bind and endocytose glycoproteins 
that have been desialylated and contain a galactose or N-acetylgalactosamine terminal residue 
[52].  According to a recent study by Mu et al., ASGPR expression was found to be considerably 
higher in hepatocellular cell lines when compared to normal hepatic cells making ASGPR an 
ideal candidate as a biomarker for HCC [53]. 
1.6.2 N-Glycosylation of ProCA to Target ASGPR 
Designed ligands for the asialoglycoprotein receptor have been evaluated by Khorev et 
al., and it was found that affinity and specificity of ASGPR and the ligands that bind are based 
on oligovalent interactions with physiological ligands [54].  This cluster glycoside effect causes 
specificity and affinity that makes ASGPR an ideal candidate for a biomarker of HCC [55].  An 
ideal ligand for ASGPR is one that is trivalent, N-acetylgalactosamine-terminated glycopeptide, 
easy to synthesize, and hydrolytically stable [54].  These qualities are important to make in vivo 
application viable.  Substrates for the asialoglycoprotein receptor have been evaluated for its 
high-capacity galactose-binding expressed on hepatocytes that bind native substrates with low 
affinity.  More potent ligands are of interest for hepatic delivery of therapeutic agents which 
were reported by Mamidyala et al. using several classes of galactosyl analogues with varied 
substitution at the anomeric, C2-, C5-, and C6-positions. Significant increases in binding affinity 
were noted for several trifluoromethylacetamide derivatives without covalent attachment to the 
protein retaining low-micromolar or better affinity for ASGPR [56].  Native ligands for ASGP 
were found to bind with low affinity including:  GalNAc, Me-Gal, and lactose.  In vivo MR 
imaging using lactose functionalized magnetoliposomes were developed and were found to have 
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hepatocyte targeting to potential aid in the diagnosis of hepatic disease; however, this was 
severely limited by non-specific uptake by kupffer cells.  Kupffer cell uptake of nanoparticles is 
such a limitation that a signal intensity change using MRI was not observed.  It is critical to 
develop an ASGPR targeted contrast agent using N-glycosylated ProCA in order to determine in 
vivo disease prognosis of hepatic disease. 
1.7 Amount of ProCA needed for Biophysical, Animal, and Human Studies 
Established expression and purification conditions, as discussed in Chapter 3, are 
important to transition into industry production of ProCA.  Clinical imaging is the long term goal 
in the development of ProCA, and it will require specific amounts of protein in order to reach 
this goal for many in vitro and in vivo studies to be performed.  In order to characterize the N-
glycosylation of ProCA, mass spectroscopy must be performed using 10 µM ProCA with a 
volume of 10 µL.  Biophysical studies for this project include florescence spectroscopy titrations 
to determine the metal binding affinity to metals such as gadolinium.  These studies require 5 - 
50 µM of 1000 µL volume ProCA.  Relaxometry is another in vitro study which requires 100 - 
500 μM of 300 μL - 1000 μL of ProCA to be performed.  MRI imaging dosage depends on the 
clearance of the contrast agent being used and an animal or human subject’s weight and it 
requires using about 100 μL to be injected with 0.50 mmol/kg for mouse or about 0.1 mmol/kg 
of 0.5 M solution dosage for human MRI.  The instruments that are used in the development of 
ProCA include:  fluorescence emission spectroscopy, relaxometer, mass spectrometer, SDS-
PAGE, and MRI for animal experiment.  These experiments require a large microgram amount 
of ProCA are required to evaluate structural and functional characteristics of ProCA.  Rose 
Augusta, a previous member of Dr. Jenny Yang’s lab, established the needed method of ProCA1 
variant expression and purification as described in her thesis [57]. 
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1.8 Purpose of the Study 
Initially in this work, previously established first generation of protein based MRI 
contrast agent, ProCA1, by Dr. Jingjuan Qiao has been expressed and purified to achieve high 
yield of ProCA for in vivo HER2/Neu targeting studies using PEGylation as an avenue to reduce 
immunogencity and to provide other added benefits as described in Section 1.6.  The main goal 
of this study is to modify Rat ProCA1 with N-glycans and characterize its in vitro biophysical 
properties as a contrast agent.  The primary objective is to understand the benefits of lysine 
modifying ProCA with PEG or glycans as a comparison.  The initial goal is to optimize the 
glycosylation process using glycans with varying chain lengths and linkers to expressed and 
purified rat ProCA1 with relatively high yield.  The secondary goal is to characterize the 
biophysical and functional properties using fluorescence metal titrations and binding studies. The 
overall goal is to develop a novel class of protein based contrast agent with reduced 
immunogenicity that has similar functional, physiological and contrasting properties as 
PEGylated ProCA with added targeting capabilities to image ASGPR in the liver. 
Chapter 1 discusses the general background and development of Protein based MRI 
contrast agent. In Chapter 2, methodologies and experimental details that are implemented for 
development ProCAs has been described. Chapter 3 describes the bacterial expression and GST 
tagged purification of first generation of ProCA and its humanized and lysine PEGylated 
targeted variant against breast cancer is evaluated, as well as, the expression and purification of 
humanized ProCA32, a third generation protein based contrast agent for MRI.  In Chapter 4, the 
lysine modification of ProCA using N-glycosylation is described.  In Chapter 5, the biophysical 
properties such as relaxivity and metal binding affinity for gadolinium is shown, as well as, the 
human serum stability and in vivo MRI enhancing capability of ProCA1 without modification, 
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PEGylated hProCA-affi, and Glyco-rProCA1 with renal clearance out the kidneys or clearance 
out the liver organs.  Chapter 6 describes the significance of this work and the future applications 
in the field of MRI imaging and possible higher affinity targeting against AGPR and overall 
whole-body imaging capabilities using glycan modified ProCA. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Lysogeny Broth 
Lysogency broth, LB, is a medium that was used in transformation, inoculation, and 
expression of ProCAs.  LB medium was prepared by the addition of 25 g of LB the one liter of 
water.  Usually for expression of a protein about 4 liters of LB is needed to obtain a large amount 
of protein for purification.  Another 250 mL of LB is needed during inoculation.  A volume of 
500 mL of LB medium is prepared for future needs along with the liters needed for expression.  
All flasks containing LB medium is autoclaved on a liquid setting for 20 minutes.  LB medium is 
allowed to cool to room temperature before being used in transformation, inoculation, or 
expression of bacteria. 
2.1.2 SDS Gel Electrophoresis 
A 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis, SDS-PAGE, is made 
for gel electrophoresis by adding 5.0 mL of 30% acrylamide/Bis to 2.5 mL of 1.5 M Tris-Cl, pH 
8.8, 0.1 mL of 10% SDS, 2.4 mL of H2O, 10 µL TEMED, and 60 µL of freshly made 10% APS 
for the stacking gel.  The resolving gel was made by adding 0.66 mL of 30% acrylamide/Bis to 
1.26 mL of 0.5 M Tris-Cl, pH 6.8, 50 µL of 10% SDS, 3.0 mL of H2O, 10 µL TEMED, and 60 
µL of freshly made 10% APS.   The samples are then boiled for 10 minutes and loaded into the 
gel using a volume of 10 µL.  A protein marker is then used by adding 5 µL.  The gel is then ran 
at 80 V until the protein passes the resolving gel.  The voltage is then increased to 120 V until 
the gel is finished running.  A coomassie blue staining buffer is then used to stain the gel by 
shaking the gel for about one hour at room temperature.  Destaining buffer is then added and the 
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gel is shaken at room temperature overnight.  The gel is then imaged the next day using a 
scanner. 
2.2 Rat ProCA1 and Humanized ProCA1 
2.2.1 Cloning Rat ProCA1  
 
Figure 2.1  Vector map of pGEX-2T of overexpressed fusion protein rat and humanized ProCA1 [58].  
The DNA sequence of rat ProCA1 (7E15) was cloned by, senior lab member Dr. Anna 
Wilkins Manicia analogously with the protocol described in her PhD dissertation [40]. A 
Gadolinium binding pocket was constructed by performing several mutations on a stable scaffold 
protein, domain 1 of rat CD2.  The mutations performed for this scaffold protein include: N15E, 
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L58D, and K64D.  The cloned DNA sequences were inserted into ampicillin resistant pGEX-2T 
vector by PCR via Dr. Jingjuan Qiao in accordance with the protocol described in her PhD 
dissertation [50].  The vector map of pGEX-2T in Figure 2.1 explains this method of 
purification.  This vector was used so a pull-down assay can be performed for the purification 
method to quickly produce high yield ProCA1 for modification.  The glutathione s-transferase, 
GST, DNA coding sequence was inserted next to the sequence coding the protein needed for 
transcription and translation so the protein is expressed as well as the GST protein creating a 
fusion protein for ease of purification.  Due to the high binding affinity of GST to glutathione, 
GSH, the fused protein can bind to GS4-B beads, and then be cleaved via thrombin, an enzyme 
that cleaves the fused GST from the ProCA1.  
2.2.2 Cloning Humanized ProCA1-affibody 
The DNA sequence of humanized ProCA1-affibody was cloned by, senor lab member 
Dr. Jingjuan Qiao in accordance with the protocol described in her PhD dissertation [50].  The 
affibody sequence ZEGFR-1907 was cloned to the C-terminal of ProCA1-CD2 in the pGEX-2T 
plasmid, as described in Section 2.2.1.  The affibody peptide consists of 58 amino acids and 13 
amino acids of them are involved in the targeting moieties, which are located in Helix One and 
Two. The sequences have been divided into three fragments and inserted into the plasmid.  The 
cloned DNA sequences were inserted in to ampicillin resistant pGEX-2T, Figure 2.1, vector by 
PCR.  
2.2.3 Transformation 
Previously amplified rat and humanized ProCA1 plasmid was transfected using 
BL21(DE3) competent cells by removing samples of competent cells from the -80 °C freezer and 
placing them on ice until thawed along with the plasmid.  Transformation was performed by 
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adding 1 µL of plasmid to 50 µL of competent cell under sterile conditions.  Samples were 
placed on ice for one hour.  Samples were then heat shocked for exactly 90 seconds at 47°C, and 
then placed on ice for 2 minutes.  Previously prepared autoclaved LB medium was added to each 
sample using a volume of 50 µL, and samples were then incubated at 37°C for 30 minutes.  
Previously prepared ampicillin containing agarose plates were then labeled and 50 µL of sample 
was spread on them using an L-shaped loop.  Plates were incubated at 37°C overnight.  The next 
morning plates were removed from incubator and stored in the refrigerator. 
2.2.4 Inoculation 
Inoculation of samples was also performed using previously prepared and autoclaved LB 
medium.  One colony from each transformation plate was inoculated in 250 mL of LB medium 
and 250 µL of 100 mg/L ampicillin for expression under sterile conditions.  Flasks of sample 
were placed in shaker at 37°C overnight.   
2.2.5 Expression 
The next day samples were removed from the shaker; then for every 1 L of fresh LB 
medium and 1 mL of 100 mg/L ampicillin 50 mL of inoculated sample from the flask was added.  
Flasks were shaken and optical density (OD) was measured periodically at 600 nm using an 
ultraviolet-visible spectrophotometer (Shimadzu UV-Visible).   Once the OD reached 0.7 - 0.9, 
300 µL of 1 M isopropyl β-D-1-thiogalactopyranoside, IPTG (1 mM), was added to each 1L 
flask.  Samples were allowed to shake at 37°C until an OD around 2.0 is reached.  Upon reaching 
an OD of 2.0, flasks of expressed protein were then centrifuged at 8,000 G for 30 minutes at 4°C.  
The cell pellet was collected and stored in -20 C and the supernatant was discarded.  A sample 
of bacteria is obtained for SDS gel electrophoresis right before IPTG is added by collecting 1 mL 
of sample from the shaking 1L flasks of bacteria.  This collected sample is then centrifuged and 
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supernatant is discarded.  The pellet is then dissolved in 120 µL of 2X SDS buffer.  More 
samples are taken in the same manner three hours after the addition of IPTG; likewise, another is 
taken around five hours after induction.  Before collecting the pellet, more samples for SDS gel 
electrophoresis is taken in the same manner as previous except 20 µL of supernatant is removed 
from the centrifuged sample and added to 20 µL of 2X SDS buffer.  The remaining supernatant 
is discarded and the pellet sample is dissolved in 120 µL of 2X SDS buffer and labeled as pellet.  
Another sample is taken before supernatant and pellet are separated in the same manner as the 
supernatant sample, except 20 µL of sample is taken before centrifugation.  This process is 
summarized in Figure 2.5. 
2.2.6 Purification 
The cell pellet was homogenized via vortex in 20 mL of lysate buffer (1% sarcosyl, 10 
mM DTT, 1 mM EDTA, suspended in PBS at pH 7.4) and 1 µL of benzonuclease.   The sample 
is then sonicated five times with one minute breaks between sonication.  The sample is then run 
through the cell disruptor twice using phosphate buffered saline, PBS, pH 7.4 to collect the 
sample from the machine.  The sample was then centrifuged for 40 minutes at 17 K rpm.  The 
supernatant is separated from the pellet and samples for SDS gel electrophoresis is taken in the 
same manner as previous for samples labeled pellet, supernatant and both.  Supernatant is then 
filtered using a 0.45 µm syringe filter.  Rat and humanized ProCA1 are glutathione s-transferase, 
GST, tagged so a GS4-B column is used to purify the protein.  The sample is ran through the 
column at least twice, and PBS is used to wash the column until it runs clear.  PBS is then added 
to the column in a volume of about 5 mL and the column is closed when thrombin is then added 
to cleave the GST from the protein.  After adding 200 µL of thrombin, (1 mg/mL in 50% 
glycerol) the columns are rotated overnight in the cold box which is kept at around 4°C.  A 
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sample before beads binding is taken for SDS to check the beads for other bound substances and 
after binding.  Samples of the waste after the protein is bound is checked for remaining protein as 
well.  These samples are prepared by adding 20 µL of sample to 20 µL of 2X SDS buffer.  The 
next day the samples are shaken at room temperature for 2-3 hours.  The protein is then eluted 
and collected.  Another 5 mL of PBS is added the column and it is again shaken at room 
temperature for an hour or two.  A second elution is then collected again.  Samples are taken for 
SDS of each elution for gel electrophoresis in the same manner as previous.  Columns are 
washed with elution buffer to remove GST.  Collected samples are checked for protein content 
using a NanoDrop spectrophotometer (ThermoFisher NanoDrop Plus).  The NanoDrop was set 
to protein measurement using a protein weight of 11.2 kDa and emission set to 11.7.  Protein 
concentration can be determined based of the peak at 280 nm, which is the absorbance recorded 
from the tryptophan and tyrosine residues contained in the protein, and the nucleotides in DNA 
strongly absorb at 260 nm creating a peak if DNA is also extracted from this method, which can 
be removed as described via FPLC. 
Fast protein liquid chromatography, FPLC, was performed to further purify protein using 
a sulfopropyl, SP, cation exchange column.  Two buffers were made:  Buffer A (50 mM NaAc 
pH at 4.0) and Buffer B (50 mM Tris pH at 7.4).  Buffer A and B were filtered to remove 
impurities and pH was adjusted.  SP column and the sample loops were washed using ddH2O.  
Buffer A was injected as a sample into the sample loops to discharge any air or residue out of the 
system. Once this was done all the protein sample was injected in to the loop. When the entire 
sample eluted out into different fragments, they were separated based on the peaks and stored at -
20 C. The system was washed with Buffer B and ddH2O to remove any remaining protein from 
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the system.  Gel electrophoresis was performed before FPLC and after to check for correct 
protein.  UV-vis was performed on each peak to check for protein concentration. 
2.2.7 Glycosylation 
The sample was dialyzed in either 10 mM PBS pH at 7.4 or 10 mM HEPES pH at 7.0 to 
prepare for N-linked glycosylation by adding the sample to 3.5 kD dialysis bags and rotating 
overnight in the cold box in two liters of buffer.  The next day the sample was then concentrated 
to the desired concentration for glycosylation.  Lactose containing sugars synthesized by 
Zhongying Xiao from Dr. George Wang’s laboratory depicted in Figure 2.2 were used in varying 
ratios of sugar to protein concentration to glycosylate rProCA1.  The synthesis of these sugars is 
modeled in Figure 2.3 which was created by Zhongying Xiao.  Molar ratios of 1:1, 2:1, 3:1, 4:1, 
5:1, 10:1, and 100:1 sugar to protein was added and rotated overnight in the cold box around 
4°C.   
 
 
Figure 2.2 Sugars used in the glycosylation modification of rProCA1. 
Sugars Used for Glycosylation of ProCA1
Sugar 1MW 1146.39 Sugar 2MW 660.23
Sugar 3MW 524.15 Sugar 4MW 700.22 Sugar 5MW 538.16
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Synthesized sugars were analyzed using proton nuclear magnetic resonance, 1H NMR, 
and carbon-13 NMR, 13C NMR, spectra recorded on a 400 MHz spectrometer.  Chemical shifts 
are reported in parts per million (ppm). NMR data is presented as follows: Chemical shift, 
multiplicity (s = singlet, d =doublet, t = triplet, dd = doublet of doublet, m = multiplet and/or 
multiple resonances), coupling constant in Hertz (Hz), integration. All NMR signals were 
assigned on the basis of 1H NMR and 13C NMR experiments. Mass spectra were recorded on an 
Applied Biosystems SCIEX MALDI TOF/TOF 5800 mass spectrometer.  Column 
chromatography was performed on silica gel G60 (Silicycle, 60-200 μm, 60Å).  TLC-analysis 
was conducted on Silicagel 60 F254 (EMD Chemicals Inc.) with detection by UV-absorption 
(254 nm) were applicable, and by spraying with 20 % sulfuric acid in ethanol followed by 
charring at ~150 ͦ C or by spraying with a solution of Hanessian’s stain followed by charring at 
~150 ͦ C. 
 
 
Figure 2.3  Synthesis of lactose donor, Sugar 5, for Glyco-rProCA1. 
 
Samples for SDS were taken before and after glycosylation in the previous manner 
mentioned.  Samples for MALDI mass spectroscopy analysis were also taken before and after 
glycosylation.  The samples were diluted with ddH2O to a concentration of 50 µM and a volume 
(NH4)2CO3,DMSO
Microwave,40oC,3 h, 80%
OOO
OH
HO
OH
OH
OH
HO OH
OH OOO
OH
HO
OH
OH
OH
HO OH
NH2 HATU, HOBt, DIPEA,DMSO, 95%
OOO
OH
HO
OH
OH
OH
HO OH
Ot-BuOHO
NH
O Ot-Bu
O
O
TFA, DCM, Anisole
90% OO
OOH
HO
OH
OH
OH
HO OH NH
O
O
OH TSTU, DIPEA, DMF
80%
OOO
OH
HO
OH
OH
OH
HO OH
NH
O
O
O N
O
O
1 2 3
4 5
47 
of 100 µL and sent for analysis to either Dr. Siming Wang or Xu Li who is also from Dr. George 
Wang’s lab. 
2.2.8 PEGylation 
ProCA1 is lysine PEGylated using 100 mM, 2 kDa, PEG and the PEG is added to the 
protein in a 5:1 molar ratio.  The sample is then shaken at room temperature for one hour.  FPLC 
is then used to purify the protein further from free PEG.  FPLC using two buffers was performed 
using an SP column.  Two buffers are also used in the column but the Buffer A contains 50 mM 
NaAc (pH=4.0) and Buffer B contains 50 mM Tris (pH=7.4).  FPLC is washed in the same way 
as previously mentioned. 
2.2.9 Relaxivity 
Relaxivity was performed by Dr. Jingjuan Qiao on Glyco-rProCA1 and ProCA1-PEG.  
Glyco-rProCA1 was first dialyzed and chelaxed using 10mM HEPES-Chelaxed buffer at pH 7.3 
for 48 hours to remove free metal ions from the protein solution. Relaxivity measurements were 
taken using fixed concentration of Gd+3 and increasing protein concentration. The T1 and T2 
relaxation time of Glyco-rProCA1 was measured by a Bruker Minispec relaxomter. The T1 is the 
time of longitudinal magnetization recovery and T2 is the time of transverse magnetization 
recovery to equilibrium along the direction magnetization. A 200 µL solution containing varying 
concentrations of contrast agents, fixed [Gd+3] and 10 mM HEPES pH 7.3 was added to a clean 
glass tube specially used for this instrument. Glass tubes were incubated in the instrument until it 
reached to equilibrium state and T1 and T2 values were measured. R1 and R2 were calculated 
using Equation 2-1. 
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2.2.10 Serum stability  
Serum stability was performed using human serum obtained from Dr. Jingjuan Qiao.  
Glycosylated rProCA1, Glyco-rProCA1, and no modification rProCA1 at a concentration of 406 
µM and 150 µL was incubated with 150 µL of human serum at 37 ͦ C.  A sample of serum only 
and Glyco-rProCA1 only was taken for SDS as previously described using 20 µL, and a before 
incubation sample at zero hours was taken of the serum and Glyco-rProCA1.  Samples were also 
take every two hours up to ten hours, and samples were also taken daily up to six days.  SDS gel 
is then ran according to previously described method in Chapter 2.1.2. 
2.2.11 Metal Binding Affinity of Gadolinium 
Fluorescence spectra were obtained using a fluorescence spectrophotometer developed by 
Proton Technology International, PTI, with a xenon short arc lamp.  Gadolinium binding of 
Glyco-rProCA1 was determined by competition titration using Fluo5N dye. Fluo-5N (Invitrogen 
Molecular Probes) is used as gadolinium indicator with a Kd of 3.8 × 10-12 M [40].  The Fluo-5N 
emission spectra were obtained by excitation at 488 nm and emission from 500-650 nm.  Fluo-
5N and Gd3+ were mixed with 1:1 molar ratio in 10mM HEPES-chelaxed buffer at pH 7.3 and 
protein was gradually titrated into the cuvette. As protein concentration increases in the system, 
the protein competes with the dye causing a decrease in the fluorescence signal. The signal 
decreases until the protein is saturated. The fluorescence intensity decrease of Fluo-5N at 520 nm 
with titration of various Glyco-rProCA1 concentrations were fitted using one to one binding 
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equation, Equation 2-2, to get an apparent dissociation constant Kapp . The Gd3+ binding affinity 
of Glyco-rProCA1 was calculated using Equation 2-3 where Kd1 is the binding affinity of Fluo-
5N and Gd3+. 
 
ሺࡼࢀାࡹࢀାࡷࢊሻିඥሺࡼࢀାࡹࢀାࡷࢊሻ ૛ି૝ࡼࢀࡹࢀ૛ࡼࢀ Equation 2-2 
ࡳ࢒࢟ࢉ࢕ି࢘ࡼ࢘࢕࡯࡭૚ିࡳ ࢇ࢖࢖ ࡷࢊ૚ࡷࢊ૚ା[ࡲ࢒࢛࢕ି૞ࡺ]ࢀ࢕࢚ࢇ࢒                Equation 2-3 
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2.3 Humanized ProCA32  
2.3.1 Cloning 
 
Figure 2.4 Map of pET-22b(+) vector for hCA32 variants overexpression [59]. 
 The DNA sequence of hCA32 was cloned into pET-22b (+) by Dr. Shenghui Xue and the 
procedure can be obtained from Dr. Shenghui Xue’s dissertation [45].The gene encoding for 
human alpha parvalbumin with two mutations, one site mutation in the EF hand binding pocket 
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and  tryptophan residue close to the binding pocket, were inserted into the pET-22b(+) vector 
between the Nde I and Xho I restriction enzyme sites. Plasmid transformation was performed on 
pET-22b (+) hCA32 in BL21 (DE3) pLysS cell strain. 
2.3.2 Transformation 
Previously amplified hProCA32 plasmid was transfected using BL21(DE3)-pLysS 
competent cells in the same manner as ProCA1 mentioned above in Section 2.2.3. 
2.3.3 Inoculation 
Inoculation of hProCA32 was done in the same procedure as mentioned above for 
ProCA1 in Section 2.2.4. 
2.3.4 Expression 
The expression procedure for hProCA32 was done in a similar manner as mentioned for 
ProCA1 in Section 2.2.5, except when OD reached 0.6-0.8 IPTG was added.  This method is 
depicted in Figure 2.5. 
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Figure 2.5 Expression of ProCA 
2.3.5 Purification 
Flasks and were removed from the shaker the next day after expression.  Flasks of 
expressed protein were then centrifuged at 8,000 G for 30 minutes at 4°C.  The cell pellet was 
collected and the supernatant was discarded.  The cell pellet was homogenized in 20 mL of 10 
mM HEPES buffer, 400 µL of 100 mM PMSF, and 1 µL of benzonuclease.   Mixture was 
sonicated eight times for one minute with five minute breaks between sonication.  A sample for 
SDS gel electrophoresis was taken after sonication by adding 50 µL of sample to 50 µL of 2X 
SDS buffer to cell pellet after the sample has been centrifuged down and supernatant was 
discarded.   The sample mixture was centrifuged for 30 minutes at 13K rpm and then boiled for 
20 minutes.  Another sample was taken after boiling for SDS in the same way.  Mixture was 
centrifuged a second time, and supernatant was collected and 3% streptomycin was added.  A 
third sample was taken after the addition of streptomycin for SDS in the same way mentioned 
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above.  The sample was refrigerated overnight and the next morning a sample for SDS was taken 
from both the supernatant and the precipitate that had formed overnight.  The sample was boiled 
again for 20 minutes, and another sample for SDS was taken.  Sample was then stirred in 10 mM 
HEPES, pH 7.3, overnight for dialysis.  Samples were checked for protein concentration by 
SDS-PAGE and UV-Vis before FPLC was performed. 
FPLC was performed to further purify protein using an anion exchange HiTrap Q 
column.  Two buffers were made:  Buffer A (10 mM HEPES at pH 8.0) and Buffer B (10 mM 
HEPES + 1.0 M NaCl at pH 8.0). Buffers were filtered to remove impurities and pH was 
adjusted. Q column and the sample loops were washed using ddH2O. The Q column and loops 
were also washed using a high salt concentration solution, Buffer B followed by the Buffer A. 
This was done at flow rate of 5 ml/min, alarm pressure at 5 mPa, Timeout at 5 min with no 
existence of bubbles. Buffer A was injected as a sample into the sample loops to discharge any 
air out of the system. Once this was done the entire protein sample was injected in to the loop 
after being filtered with a 0.45 µm syringe filter. When the entire sample eluted out into different 
fragments, they were separated based on the peaks and stored at -20 C. The system was washed 
with Buffer B and ddH2O to remove any remaining protein from the system.  SDS-PAGE was 
again performed after FPLC to check for the correct protein.  Spectrophotometry was performed 
on each peak to check for protein concentration.   
Peaks 2 and 3, as shown in Figure 3.8, were concentrated because these are the ProCA32 
containing peaks.  Sample was concentrated all the way down to remove any nucleic acid 
fragments in the solution, and then 1 mL of 10 mM HEPES was added and sample was 
concentrated down a second time.  HEPES was added again of the same volume and SDS-PAGE 
as well as UV-Vis was performed to check protein concentration. 
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3     EXPRESSION AND PURIFICATION OF FIRST AND THIRD GENERATION 
DESIGNED PROTEIN BASED MRI CONTRAST AGENTS  
3.1 Introduction 
As shown in Chapter 1, application of ProCAs to preclinical and clinical applications and 
biophysical studies requires a large amount of protein to be produced.  Often production of 
protein amounts for the application is a bottle neck.  Protein expression refers to the way proteins 
are synthesized, modified and regulated in organisms; however, in the context of laboratory 
research usually this is in regards to the manufacturing of proteins for further synthetic 
modification, analysis and application.  Previously in Chapter 1, it was discussed that Rat and 
Humanized ProCA1 are first generation protein based contrast agents.  The scaffold protein is 
based off the protein CD2 domain 1 from rat and human respectively.  Various mutations to this 
protein have been used to build a gadolinium binding pocket that can be utilized in MRI.    An 
established protocol for time efficient and cost effective high yield protein has already been 
developed by previous lab member, Rose Augusta [57].  This established protocol was further 
adjusted to envelope the modification of rProCA1 using lysine modification discussed in Chapter 
4.  Previous members such as Kendra Hubbard and Anvi Patel have also established protocols 
for expression and purifications of ProCA32 that is a third generation protein based contrast 
agent that has two gadolinium binding pockets [29, 30].  This contrast agent’s scaffold protein is 
parvalbumin, a calcium binding protein, in which calcium binding pockets have been mutated to 
create the gadolinium binding pockets used for MRI [29].  In this chapter, the expression results 
will confirm the previously established protocol for expression of rProCA1, hProCA1, and 
hProCA32 in LB medium using E. coli competent cell as described in Chapter 2.  The 
purification method of using GST tag protein purification system will be evaluated as effective at 
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achieving a high yield, pure protein when purifying first generation ProCA.  The characterization 
and application of ProCAs will be described in Chapters 4 and 5 respectively.  
3.2 Results and Discussion 
3.2.1 Expression and Purification of Rat ProCA1 
Rat ProCA1 7E15 variant was cloned into the GST tagged pGEX-2T vector as described 
previously in Section 2.2.1.  This DNA containing plasmid was then expressed in competent cell 
E. coli strain BL21(DE3) as described in Sections 2.2.3, 2.2.4, and 2.2.5.  Overexpression of 
rProCA1 using the GST pull-down assay method is required for rapid purification of high yield 
protein as shown in Figure 3.1.  The left image depicts the SDS-PAGE electrophoresis, stained 
with coomassie blue, of large scale expression over time of protein using E. coli expression 
method.  A small scale expression method was not needed, as this protein is well established for 
high yield protein with known overexpression using an established method.  The GST tagged 
rProCA1 fusion protein expression can clearly be seen in this image boxed in with red to 
highlight the band of interest at 37.2 kDa.  The standard used in this SDS-PAGE gel is a 
homemade marker which uses GST at 26 kDa for better analysis of this protein, as the protein is 
a GST fusion protein.  In Figure 3.1, the image on the right depicts the OD curve of the 
overexpression of this protein over time at an absorbance of 600 nm.  Samples were taken before 
and after induction, as well as at induction circled in red.  This curve is the expected curve for E. 
coli expression which is known to have four stages of expression including the lag phase, log 
phase, stationary phase and death phase.  The OD curve depicted in Figure 3.1 show all of the 
phases listed, with exception to the death phase due to the collection of bacteria cells before the 
death phase begins at an OD of 2.0. 
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Figure 3.1 Expression of rProCA1 SDS-PAGE electrophoresis and OD curve.  Left: SDS-PAGE electrophoresis (15%) gel of each sample taken during large scale expression of rProCA1 in BL21(DE3) E. Coli competent cells.  The standard is represented in red and lanes are as follows reading left to right:  marker, before induction (addition of IPTG) Flask 1, before induction Flask 2, 1 hour after induction Flask 1, 1 hour after induction Flask 2, combined flasks supernatant (no protein containing sample), blank lane, combined flasks pellet (protein containing sample).  The red box highlights the protein band at 37.2 kDa (before GST cleavage).   Right:  UV-Visible spectroscopy analysis of cell growth using an OD curve taken at different time frames at absorbance of 600 nm.  
 
Purification of rProCA1 as described in Section 2.2.6 is a purification method using GST 
tagged method pull down assay.  Rapid expression of this protein creates large amounts of cell 
membranes expressed that can be broken during cell lysis using sonication and cell disruption.  
This releases cellular components including the desired protein that must be extracted via 
purification.  Centrifugation of the sample after cell lysis allows the solubilized contrast agent, 
rProCA1, as well as other water soluble cellular components to separate from the insoluble in the 
form of a supernatant and cell pellet as depicted in the left image of Figure 3.2 by SDS-PAGE 
gel.  The pure supernatant lane of this gel is the soluble contrast agent containing protein, while 
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the pure pellet lane shows a remaining protein trapped in the insoluble cellular components.  The 
insoluble pellet is discarded and the soluble supernatant is collected for further purification from 
DNA and other undesired protein.  Removal of remaining undesired protein from the desired 
contrast agent is achieved by using the GS4B column in the procedure previously described in 
Section 2.2.6.  After the supernatant sample has been filtered, the sample is then run through a 
pull down assay using GS4B columns.  In Figure 3.2, the right image shows the SDS-PAGE 
electrophoresis of this purification.  Wash Lanes 1 and 2 are taken after the sample is runs 
through the columns.  This sample contains unwanted protein and DNA contamination that is 
removed.  The sample in lanes three and four contain the beads bound to the column.  In this 
sample a strong band around 37.2 kDa is seen.  The column is rinsed with PBS to remove any 
remaining unwanted protein, and then thrombin is added to elute the pure contrast agent.  Lanes 
5-8 of this gel shows the purified protein eluted twice from the GS4B columns, after rotation 
overnight.  These lanes exhibit only a strong band around 11.2 kDa, indicating the purification of 
a very pure protein.  After the cleavage of the desired protein is achieved, thrombin must be 
removed using FPLC as described in Section 2.2.6.  Figure 3.2, left image, shows the pure 
protein imaged by SDS-PAGE electrophoresis in lane nine of this gel.   
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Figure 3.2 Purification of GST tagged rat ProCA1 SDS-PAGE electrophoresis.  SDS-PAGE electrophoresis (15%) gel of each sample taken during purification of rProCA1 in BL21(DE3) E. Coli competent cells.  The standard is represented in red. Left:  Lanes are as follows reading left to right:  supernatant after cell lysis, pellet after cell lysis, both supernatant and cell pellet after cell lysis, marker.  The red box highlights the protein band at 37.2 kDa (before GST cleavage).  Right:  Lanes are as follows reading left to right:  wash of column one, C1, after running sample through GS4-B column; wash of column two, C2; beads bound of C1; beads bound of C2; C1 elution one when thrombin was added to elute rProCA1 from the GS4-B column; C2 elution one; C1 second elution; C2 second elution; FPLC sample; and marker.  The red box highlights the protein band at 11.2 kDa (after GST cleavage).  
 
The single band shown in the SDS-PAGE gel, along with Figure 3.3, indicates a very 
pure, high yield protein was purified using the GST tagged method.  Figure 3.3, left image, 
depicts the chromatogram of the FPLC system SP column used to purify the contrast agent from 
the contaminated DNA and remaining thrombin.  This is achieved because the SP column is a 
cation exchange column.  In this method of chromatography, the positively charged molecules, 
contrast agent, will be attracted to a negatively charged column.  The contrast agent, as per 
Section 2.2.6, is positively charged at a pH of 3.0.  In order for the maximum allowed amount of 
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contrast agent to bind, a mobile phase with a salt buffer is used to drive the interactions of the 
highly charged molecules to will bind more efficiently with the column, while the weaker ionic 
interaction molecules will elute from the column first.  Figure 3.3, left image, shows this 
phenomenon in the form of the first peak of the chromatogram.  This peak is the DNA eluting 
from the column, while the desired protein remains bound.  For the desired protein to be 
released, a change of pH is created causing the column bound molecules to become less 
protonated in order to break away from the column.  The contrast agents elutes from the column, 
as shown in the figure.  In Figure 3.3, the FPLC chromatogram depicts the contrast agent circled 
in red eluting from the column and forming a high yield, very pure peak. 
Figure 3.3, right panel, depicts the high yield, very pure desired contrast agent after 
purification using the GST tagged method and after FPLC purification to remove the remaining 
contaminants that were not removed or that were created (thrombin) using the GST tagged 
method.  This UV-vis spectrum was created using a NanoDrop spectrophotometer.  The peak 
generated at 280 nm and circled with red in the figure, is the protein peak as previously described 
in Section 2.2.6.  This peak is generated by tryptophan and tyrosine residues in the protein 
sequence.  The peak at 230 nm is the peak usually generated by a protein sample as many 
organic compounds, including peptide bonds in proteins, absorb light around 200-230 nm.  The 
NanoDrop was configured to automatically generate the concentration of the contrast agent by 
choosing “other protein” option and manually entering the molar extinction coefficient at 11.7 
M-1 cm-1- and molecular weight at 11.2 kDa for the protein.  The NanoDrop calculated the 
protein concentration to be 4442 µg/mL.  The final yield of this protein purification was 
calculated to be 6.11 mg/L. 
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Figure 3.3  Purification of GST tagged rProCA1 FPLC chromatogram and UV-vis spectrum.  Left:  FPLC chromatogram of GST tagged rProCA1 purification using an SP ion exchange column.  The first peak is elution of DNA contamination, and the second peak, highlighted by the red circle, is the elution of the purified protein, rProCA1. Right:  UV-vis spectrum of GST tagged rProCA1 purified sample after FPLC using the NanoDrop instrument.  Peak at an absorbance of 280 nm, circled in red, indicates a protein peak; while, an absorbance peek at 260 nm would indicate a DNA contamination peak.  Absorbance at 280 nm was determined to be 4.640, indicating a protein concentration of 4442 µg/mL.  
3.2.2 Expression and Purification of Humanized ProCA1-affi 
Humanized ProCA1-affi was cloned into the GST tagged pGEX-2T vector as described 
previously in Section 2.2.1.  This DNA containing plasmid was then expressed in competent cell 
E. coli strain BL21(DE3) as described in Sections 2.2.3, 2.2.4, and 2.2.5.  Overexpression of 
hProCA1-affi using the GST pull-down assay method is required for rapid purification of high 
yield protein as shown in Figure 3.4.  The left image depicts the coomassie blue stained SDS-
PAGE electrophoresis of large scale protein expression over time using E. coli expression 
method.  A small scale expression method was not needed, as this protein has been established 
for high yield protein with known overexpression using an established method.  The GST tagged 
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hProCA1-affi fusion protein expression can clearly be seen in this image boxed in with red to 
highlight the band of interest at 44.7 kDa.  The standard used in this SDS-PAGE gel is a 
homemade marker which uses GST at 26 kDa for better analysis of this protein, as the protein is 
a GST fusion protein.  In Figure 3.4, the image on the right depicts the OD, OD, curve of the 
overexpression of this protein over time at an absorbance of 600 nm.  Samples were taken before 
and after induction, as well as at induction circled in red.  This curve is the expected curve for E. 
coli expression which is known to have four stages of expression including the lag phase, log 
phase, stationary phase and death phase.  The OD curve depicted in Figure 3.4 show all of the 
phases listed, with exception to the death phase due to the collection of bacteria cells before the 
death phase begins at an OD of 2.0. 
 
 
Figure 3.4 Humanized ProCA1-affi expression SDS-PAGE  SDS-PAGE electrophoresis (15%) gel of each sample taken during purification of hProCA1-affi in BL21(DE3) E. Coli competent cells.  The standard is represented in red. Left:  Lanes are as follows reading left to right:  standard, before induction Flasks 1-2, one hours after induction Flasks 1-2, marker, four hours after induction Flasks 1-2, supernatant, and cell pellet.  The red box highlights the protein band at 44.7 kDa (before GST cleavage).  Right:  UV-Visible spectroscopy analysis of cell growth using an OD curve taken at different time frames at absorbance of 600 nm. 
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The double band shown in the SDS-PAGE gel, along with Figure 3.5, indicates a pure 
protein with remaining thrombin purified using the GST tagged method; however, a band around 
6 kDa is shown indicating there is thrombin in the sample because the sample was not yet 
purified from the thrombin cleavage reagent using FPLC.  Figure 3.5, right, depicts the UV-vis 
spectrum of hProCA1-affi after GST cleavage.  In Figure 3.5 the protein peak at 280 nm 
indicates a pure, high yield protein in this sample free from contaminated DNA and the 
remaining thrombin will be removed after PEGylation later using FPLC.  Protein concentration 
was calculated using the theoretical value obtained based on primary amino acid sequence using 
an online database protein calculator (available at 
http://www.basic.northwestern.edu/biotools/proteincalc.html).  The concentration of this sample 
was found to be 23 µM with a final protein yield to be determined after PEGylation and FPLC 
purification in the next step. 
 
Figure 3.5 Purification of GST tagged hProCA1-affi SDS-PAGE electrophoresis.  SDS-PAGE electrophoresis (15%) gel of each sample taken during purification of hProCA1-affi in BL21(DE3) E. Coli competent cells.  The band at 18.7 kDa in lanes Elution 1 and Elution 2 represent the purified protein.  The standard is represented in red. 
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Left:  Lanes are as follows reading left to right:  marker, wash of column one, wash of column 2, elution one, elution two.  The protein band at 18.7 kDa (after GST cleavage) is shown; as well as, the 6 kDa band for thrombin. Right:  UV-vis spectrum of GST tagged hProCA1-affi purified sample after GST cleavage.  Peak at an absorbance of 280 nm indicates a protein peak; while, an absorbance peek at 260 nm would indicate a DNA contamination peak.    
Figure 3.6, left image, depicts the PEGylated results using SDS-PAGE electrophoresis.  
The sample before PEGylation in this Figure 3.6, left, shows a protein band around 18.7 kDa 
with a second band for thrombin around 6 kDa; however, after the sample is PEGylated, the 
protein will be further purified using FPLC, as show in Figure 3.6 (right)., which depicts the 
chromatogram using FPLC ion exchange column.  The first peak in the chromatogram is DNA, 
thrombin, or remaining free PEG eluting from the column, and the second peak is the pure 
PEGylated hProCA1-affi desired contrast agent after purification using the GST tagged method 
and after FPLC purification to remove the remaining contaminates that were not removed or that 
were created (thrombin) using the GST tagged method.  The protein yield was found to be 3.01 
mg/L. 
 
Figure 3.6 PEGylation of hProCA1-affi SDS-PAGE electrophoresis gel and chromatogram.  
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Left:  SDS-PAGE electrophoresis (15%) gel of each sample taken after PEGylation of hProCA1-affi using 2.4 kDa lysine PEG.  The standard is represented in red.  Lanes are as follows reading left to right:  Before PEGylation hProCA1-affi, PEGylated hProCA1-affi before FPLC, sample 45 of FPLC PEGylated hProCA1-affi, sample 46, 47, 48, 49, 50, and marker.  The the protein band before PEGylation is around 18.7 kDa (after GST cleavage) and after PEGylation the band increases in increments of 2 kDa as various lysine residues are PEGylated heterogeneously in the sample.  Right:  FPLC chromatogram of PEGylated hProCA1-affi purification using an SP ion exchange column.  The first peak is elution of DNA contamination, and the second peak, highlighted by the red circle, is the elution of the purified protein, PEGylated hProCA1-affi.  The protein yield is found to be 3.01 mg/L.   
3.2.3 Expression and Purification of Humanized ProCA32 
Humanized ProCA32 was cloned into the vector as described previously in Section 2.3.1.  
This DNA containing plasmid was then expressed in competent cell E. coli strain BL21(DE3)-
pLysS as described in Sections 2.3.3, 2.3.4, and 2.3.5.  Following the successful transformation 
of pET-22b (+)-hProCA32 gene into BL21 (DE3)-pLysS competent cells, the increasing OD of 
the cell culture can conclude that the bacterial cells grew fairly well at 37 °C before induction 
and at 25 °C after induction as indicated by the OD curve in Figure 3.7, right.  The 15 % SDS-
PAGE gel in Figure 3.7, left, shows faint bands around 12 kDa prior to induction in both 
competent cells indicative of leaky expression. The heavier band on the gels corresponding to 
samples 3 hours after IPTG addition indicates that a significant amount of hProCA32 protein was 
overexpressed. 
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 Figure 3.7 Humanized ProCA32 expression SDS-PAGE.  SDS-PAGE electrophoresis (15%) gel of each sample taken during purification of hProCA32 in BL21(DE3)-pLysS E. Coli competent cells.  The standard is represented in red. Left:  Lanes are as follows reading left to right:  standard, before induction Flasks 1-4, three hours after induction Flasks 1-4.  The red box highlights the protein band around 12 kDa. Right:  UV-Visible spectroscopy analysis of cell growth using an OD curve taken at different time frames at absorbance of 600 nm.  
 Due to high negative charge, hProCA32 is highly soluble and stays in the supernatant 
after breaking the cell by sonication, as shown in Figure 3.8, left. On the other hand, nucleic 
acids are also highly negatively charged and remain soluble in the supernatant. The main goal is 
to isolate a well-folded, pure and functional form of this contrast agent. After breaking the cells 
in lysis buffer containing protease and benzonuclease, the mixture was centrifuged to collect the 
supernatant. Although hProCA32 is soluble, there are some other unwanted proteins that are also 
soluble and remain in the supernatant after sonication as seen in the SDS-PAGE.  The next step 
is to separate the nucleic acids that coexist along with the contrast agent (verified by UV 
absorbance). The supernatant was treated with 3% streptomycin sulfate (optimized 
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concentration), which is an antibiotic that binds to the nucleic acids and precipitates them out. 
The supernatant was again heated for another 20 minutes to get rid of any possible unwanted 
proteins and dialyzed in 10 mM HEPES pH 8.0 prior to purification by anion exchange on a Q- 
column, depicted in Figure 3.8, right bottom.  The SDS PAGE for each eluted peak of the protein 
is also imaged in Figure 3.8, right top.  This protein elutes out both the apo (Ca2+ free) and holo 
(Ca2+ loaded) protein forms.  The lane labeled as 2 in this figure is the holo-form of hProCA32 
and the lane labeled as 3 is the apo-form confirmed by previous lab members [29].  The last peak 
in the figure, Peak 5, contains DNA.  Since hProCA32 is originally a calcium binding protein, it 
may bind to free calcium ions that are naturally present in the purification buffers and the 
presence of a mixture of calcium bound form and calcium free form in the protein solution might 
affect the Gd3+ binding and skew the results for metal binding studies.  The holo-form of the 
contrast agent will have less total negative charge compared to the apo-form of the contrast agent 
making the calcium bound form elute out first, Peak 2, the salt gradient is first introduced in to 
the program followed by the calcium free form, Peak 3.            
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Figure 3.8 Purification of hProCA32 SDS-PAGE electrophoresis and chromatograph.  SDS-PAGE electrophoresis (15%) gel of each sample taken during purification of hProCA32 in BL21(DE3)-pLysS E. Coli competent cells.  The standard is represented in red. Figure A:  Lanes are as follows reading left to right:  marker, sonicated cell pellet, sonicated supernatant, boiled cell pellet, boiled supernatant, supernatant after streptomycin was added, precipitate after streptomycin was added, and boiling sample.  The protein band around 12 kDa. Figure B:  SDS-PAGE electrophoresis gel after FPLC purification lanes read left to right as follows:  marker, sample before FPLC, Peak One of FPLC sample, Peak Two of FPLC sample, Peak Three, Peak Four, and Peak Five. Figure C:  FPLC chromatogram of hProCA32 purification using an anion exchange Q column salt gradient.  The first peak is elution of DNA contamination or unbound protein, and the second peak is the elution of the purified protein in holo (calcium bound) form, the third peak is the apo (calcium free) purified protein peak.  
 
 The purification protocol for rat ProCA32, previously established by Dr. Shenghui Xue 
suggests nucleic acid fragments remaining after FPLC could be removed by concentrating the 
solution several times using Amicon nitrogen concentrator with 3kDa membrane.  This method 
was also implemented with the humanized ProCA32.  In the UV spectrum of Figure 3.9, left, a 
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spiky shoulder at 285-295 nm corresponds to the holo-form and Figure 3.9, right, shows a 
flattened shoulder indicating the presence of apo-form of the contrast agent.  The yield obtained 
for humanized ProCA32 combined with the apo and holo form of the contrast agents was 9.04 
mg/L. 
  
 Figure 3.9 The UV spectra of calcium free (left) and calcium loaded (right) form of hProCA32 (10 mM HEPES, pH 7.3).  Peak 2 (left) was concentrated to 1.39 mM and Peak 3 (right) was concentrated to 1.90 mM with a final total combined yield of 9.038 mg/L of hProCA32.  
3.2.4 Purification and Property Comparison ProCA Variants 
Each ProCA expressed in this chapter is summarized in Table 3.1 with the final 
calculated yield.  In this table ProCA32 was found to have the highest yield; however, 
humanized ProCA1 has not yet been optizimed for expression and purification.  The creation of 
protein based MRI contrast agents have been in development for many generations in this lab.  
The first generation of ProCA was intended to be a novel class of contrast agents by designing a 
Gd3+ binding pocket into the protein scaffold to bind gadolinium and other lanthanides.  The 
selection of a scaffold protein prior to building a Gd3+ binding pocket is extremely important 
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prior to contrast agent design.  The first generation ProCA scaffold protein was based on rat and 
human CD2 Domain 1 for each rProCA1 and hProCA1 generation contrast agent respectively.  
Each scaffold protein exhibits stability, solubility, and tolerance to mutation.   
 
Table 3.1 Final yield summary of each ProCA variant. 
 
 
The optimization of rProCA1 using various E.coli cell strains for expression and 
purification was developed by previous lab members.  This method of expression and 
purification using BL21 (DE3) competent cells gave a final protein yield of 6.11 mg/L for further 
studies using N-glycosylation lysine modification.  In order to compare the results from these 
studies, the humanized version of this contrast agent was expressed and purified.   
The humanized version of ProCA1 was created by Dr. Jingjuan Qiao with a goal of 
reducing immunogenicity and grafting a targeting affibody onto the contrast agent to target 
HER2/Neu FDA approved biomarker.  This was further optimized with the addition of 
PEGylation lysine modification onto the humanized ProCA1, leading to a further increase of r1 
and r2 relaxivities and a 100-fold improvement in in vivo dose efficiency, in addition to a 
reduction in immunogenicity and an increase in solubility.  This HER2-targeted MRI contrast 
agent was created by adding a HER2-specific affibody moiety into the designed protein contrast 
agent.  This contrast agent was expressed, purified, and lysine PEGylated with 2.4 kDa PEG with 
a final yield of 3.01 mg/L.  This protein will be optimized in a future study. 
For the third generation of ProCA, we have selected parvalbumin as a scaffold protein.  
Parvalbumin is naturally a calcium binding protein that also has the capability of binding 
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lanthanides.  Previously, a series of third generation of ProCA were designed by Dr. Shenghui 
Xue, out of which ProCA32 variant showed a significantly high relaxation both in vitro and in 
vivo [60]. In developing a protein based contrast agent the next step would be to humanize it with 
the goal of reducing the immunogenicity effects in humans. We have designed ProCA32 using 
the human sequence of parvalbumin with necessary mutations.  The expression of humanized 
ProCA32 has been optimized using various E.coli cell strains by previous lab members.  This 
protein was expressed in BL21 (DE3)-pLyS competent cells with a finial protein yield of 9.04 
mg/L. 
Both generation of ProCA, ProCA1 and ProCA32 have various benefits and drawbacks 
to their utilization as contrast agents for MRI.  ProCA1 and ProCA32 have capabilities of being 
utilized as a targeting contrast agent by grafting an affibody onto the contrast agents.  These 
contrast agents also have been to be modified using lysine modification to improve r1 and r2 
relaxivities, improvement in in vivo dose efficiency, reduced immunogenicity, and an increase in 
solubility.  ProCA32 has been optimized further using a cysteine site specific PEGylation 
modification in order to develop a homogenously modified protein.  ProCA1 contains many 
lysine residues and cannot be homogenously modified using this method; however, this is an 
important development in order to push into the clinical arena.  ProCA1 has been found to have 
lower metal binding affinity to gadolinium than ProCA32.  ProCA32 has demonstrated strong 
Gd3+ binding affinity with Kd of 10-22 M, while ProCA1 only demonstrates Gd3+ binding affinity 
with Kd of 10-12 M [29].  This could be due to the natural metal binding capability of the scaffold 
parvalbumin.  ProCA32 also exhibits high relaxivity due to the two metal binding pockets to 
increase pay load in comparison to ProCA1.   
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3.3 Conclusion 
In summary first generation rat and humanized ProCA variants have been expressed and 
purified at a final protein yield of 6.11 mg/L and 3.01 mg/L respectively.  Third generation 
humanized ProCA32 was also expressed and purified with a final protein yield of 9.04 mg/L.  
These contrast agents have been under development for many years in this lab using different 
method of purification.  First generation ProCA are purified using GST tagged method; while, 
third generation ProCA are purified using a taggless method.  These methods of purification lead 
to a more stable and well folded protein therapeutic limiting toxicity for clinical trials.  
Humanized ProCA1 was then further modified using lysine PEGylation to further increase 
protein stability with many other added benefits as discussed in Chapter 1.  Rat ProCA1 will also 
be further modified using glycosylation with lactose for stability and ASGPR targeting 
capabilities.  This modification is evaluated in Chapter 4 and the application of these 
modification to preclinical and biophysical studies are discussed in Chapter 5. 
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4 GLYCAN LYSINE MODIFICATION OF PROCA1 FOR IMPROVED STABILITY 
AND TARGETING 
4.1 Introduction 
It was found, similarly to PEGylation, glycosylation provides a large hydration shell 
capable of protecting proteins from proteolysis and glycosylation has the added benefit of being 
able to stabilize the protein by forming hydrogen bonds with a protein’s amino acid residues as 
discussed in Chapter 1 [38].  These added benefits along the biodegradability of glycosylation 
make this method an attractive alternative to decreasing immunogenicity and increasing dose 
efficiency, circulation half-life, and solubility of ProCA.  In addition, glycosylation also plays an 
important role in the discovery of biomarkers for carcinoma.   
As discussed previously in Chapter 1, biomarkers like ASGPR can be used to evaluate 
the growth of a carcinoma in vivo.  Continuous research into cancer biomarkers provides and 
avenue for evaluation and diagnosis of disease development and detection.  Lectins and glycans 
are important biomarkers for disease diagnosis, progression, and drug treatment.  Lewis Y (LeY), 
sialyl carbohydrates (SLex, and SleA), lectins, such as ASGPR, and galectins are correlated with 
the presence, stage, and metastatic potentials of various types of cancers and other diseases.  We 
have to probe further into this to see if there is an affinity ligand like lactose that can be used to 
target disease biomarkers like lectins and detect it using imaging methodologies for disease 
diagnosis.  However, in order to establish glycosylation of ProCA an easily synthesized lactose 
targeting moiety was used in our studies to determine if N-glycosylation of ProCA would be 
successful.  One of the challenges with probing further for an affinity ligand to ASGPR is native 
substrates of ASGPR like lactose, N-acetylgalactosamine (GalNAc), and methylated galactose 
(Me-Gal) have a low binding affinity to ASGPR with Kd values of 257 ± 23 µM, 40.4 ± 9.5 µM, 
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and 880 ± 200 µM respectively [56].  One way to overcome this problem is to have a multivalent 
sugar design that will bind ASGPR with much higher affinity and specificity.   
As shown in Chapter 3, we have expressed and purified Rat ProCA1.  This generation of 
ProCA contains six lysine residues (red) as shown in Figure 4.1 with the protein structure 
adapted from the RCSB protein data bank, PDB [42].  The yellow residues in this figure 
represent the metal binding pocket, and the green chains are the 3D representations of sugar 5, 
lactose, covalently bonded onto ProCA and discussed in more detail in this Chapter.  Our 
modification design has previously shown that only three lysine modifications are possible due 
to the limited accessibility of three residues to the solvent [37].  This figure shows the lactose 
modification design of rProCA1 and the major focus of this chapter.  
 
 
Figure 4.1 Schematic of Glycosylation of Rat ProCA1 using Lactose.  
Several glycans, shown in Figure 2.2, were designed in order to establish a successful 
linker to N-glycosylate ProCA1 with varying carbohydrate lengths.  These sugars were 
characterized using both 1H NMR and 13C NMR and MALDI mass spectroscopy.  Rat ProCA1 
74 
was N-glycosylated, and analyzed by MALDI mass spectroscopy, with a terminal galactose with 
varying chain lengths and linkers, show in Figure 2.2, to optimize lactosylating rProCA for 
targeting ASGPR in the liver.  The synthesis of these designed lactose moieties is shown in 
Figure 2.3.  This chapter establishes a novel modification method which can improve stability 
with targeting capabilities further discussed in Chapter 5. 
4.2 Results and Discussion 
4.2.1 Glycan Design for Glycosylation of rProCA1 
Described previously in Section 2.2.7, Sugar 5 was synthesized by Zhongying Xiao from 
Dr. George Wang’s laboratory in the method described using an NHS reactive linker group 
which will covalently bond onto ProCA lysine residues.  Other sugars were also used to 
determine the best linker design with varying carbohydrate chain lengths.  The confirmation of 
the synthesized compounds in Figure 2.3 were evaluated using both 1H NMR and 13C NMR.  
The characterization Compound 3 are as follows:   
1H NMR (400 MHz, D2O):  δ = 4.90 (d, J = 9.24 Hz, 1H), 4.38 (d, J = 7.76 Hz, 1H), 3.86-3.83 
(m, 2H), 3.74 (t, 1H), 3.71 (t, 1H), 3.69 (m, 2H), 3.66-3.57 (m, 5H), 3.47 (dd, 1H), 3.36 (m, 1H), 
2.73 (s, 1H), 2.64 (s, 1H), 2.52 (s, 2H), 1.36 (s, 9H) 
13C NMR (100 MHz, D2O):  δ=176.13, 174.22, 102.87, 82.83, 76.26, 75.09, 70.94, 68.56, 61.05, 
59.88, 59.87, 38.72, 38.00, 30.33, 30.24, 27.18.  The 1H NMR and 13C NMR spectrums of these 
characteristics can be seen in Figures 4.2 and 4.3 respectively. 
The characterization of Compound 4 are as follows: 
1H NMR (400 MHz, D2O):  δ = 4.88 (d, J = 9.20 Hz, 1H), 4.35 (d, J = 7.76 Hz, 1H), 3.84-3.81 
(m, 2H), 3.73-3.66 (m, 4H), 3.63-3.55 (m, 5H), 3.45 (t, 1H), 3.34 (t, 1H), 2.61-2.54 (m, 4H) 
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13C NMR (100 MHz, D2O):  δ = 176.90, 176.05, 102.85, 79.09, 75.03, 71.46, 68.53, 61.02, 
59.86, 30.10, 28.69.  The 1H NMR and 13C NMR spectrums of these characteristics can be seen 
in Figures 4.4 and 4.5 respectively. 
 
 
Figure 4.2 1H NMR spectrum of Compound 3. 
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Figure 4.3 13C NMR spectrum of Compound 3.  
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Figure 4.4 1H NMR spectrum of Compound 4.    
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Figure 4.5 13C NMR spectrum of Compound 4.  
To establish a method of glycosylation, different molar ratios of sugar to protein were 
used in the glycosylation of rProCA1, as described in Section 2.2.7.  Figure 2.2 depicts the 
various sugars used to glycosylate the contrast agent.  These sugars vary in chain length and 
linkers to attach to the contrast agent.  All sugars were experimentally evaluated using MALDI 
mass spectroscopy and SDS-PAGE electrophoresis to determine the best way to glycosylate this 
contrast agent.  Varying molar ratios of sugar to protein were initially evaluated using SDS-
PAGE electrophoresis.  Figure 4.6 depicts these results using four different sugars with various 
chain lengths and linkers as shown in Figure 2.2.  Sugars 1-3 were evaluated using the same 
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conditions to determine the best molar ratio, chain length, and linker.  Sugar 1 is the only sugar 
that had a molecular weight large enough to determine glycosylation using SDS-PAGE 
electrophoresis.  Sugars 2 and 3 had a molecular weight too small to determine glycosylation 
using SDS-PAGE electrophoresis.  It was determined that a much larger ratio of sugar to protein 
must be used to glycosylate the contrast agent, as well as a different method for evaluating 
glycosylation must be used, such as MALDI mass spectroscopy when evaluating sugars with a 
low molecular weight.  Sugar 4 was then used to glycosylate rProCA1 with a molar ratio of 50:1.  
Samples of Sugars 1-3 with a molar ratio of 5:1 were sent for MALDI mass spectroscopy 
analysis, as well as Sugar 4 with a molar ratio of 50:1. 
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 Figure 4.6 Glycosylation of rProCA1 SDS-PAGE results using different molar ratios.  SDS-PAGE electrophoresis (15%) gel of each sample taken for varying molar ratios during glycosylation of rProCA1.  The standard is represented in red.  The lanes read as follows from left to right. Sugar 1:  Lane One is the standard, Lane Two is the before glycosylation sample, Lane Three is the sample after a molar ratio glycosylation of 1:1 sugar to protein, Lane Four is the ratio of 2:1, Lane Five is the ratio of 3:1, Lane Six is the ratio of 4:1, and Lane Seven is a molar ratio of 5:1.  This sugar exhibits a molecular weight of 1146.39 Da.  This separation is shown by the small band above the thick band normally exhibited by rProCA1.  This indicates successful partial glycosylation. Sugar 2:  Lane One is the sample before glycosylation was performed, Lane Two is the molar ratio of sugar to protein 1:1, Lane Three is the 2:1 sample, Lane Four is the standard, Lane Five is the 3:1 ratio, Lane Six is the 4:1 sample, and Lane Seven is the 5:1 sample.  The sugar used in this glycosylation only has a molecular weight of 660.23 Da.  This is too small of a change in molecular weight to determine glycosylation based off SDS-PAGE electrophoresis. Sugar 3:  Lane One is the sample before glycosylation, Lane Two is the 1:1 molar ratio, Lane Three is the 2:1 molar ratio, Lane Four is the marker, Lane Five is the 3:1 ratio, Lane Six is the 4:1 molar ratio, and Lane Seven is the 5:1 molar ratio.  The molecular weight of this sugar is also too small to see glycosylation bands based off the SDS-PAGE gel at 524.15 Da. Sugar 4:  Lane One is the standard, Lane Two is the before glycosylation sample, and Lane Three is the 50:1 molar ratio of sugar to protein.  The molecular weight of this protein is 700.22 Da.  There is a clear separation of the two bands in the third lane indicating that half of the sample was successfully glycosylated, increasing the molecular weight from the original contrast agent.    Figure 4.7 examines the MALDI analysis of the glycosylation of rProCA1 using Sugar 1.  
The left image is the MALDI spectrum of the contrast agent before modification.  The right 
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image depicts the MALDI spectrum of the contrast agent after glycosylation with Sugar 1.  The 
spectrum on the left exhibits a pure protein with a doublet peak at 5654.214 Da and a singlet 
peak at 11307.549 Da.  The spectrum on the right also shows a doublet peak for the contrast 
agent at 5656.101 Da, a singlet for the contrast agent at 11310.701 Da, and a glycosylated peak 
of the contrast agent at 12572.599 Da.  The difference in the labeled Glyco-rProCA1 peak and 
the labeled rProCA1 peak is 1261.90 Da.  This is consistent with establishing the successful 
glycosylation of rProCA1 at 1 % based off the intensities of the peaks within the Glyco-rProCA1 
MALDI Sugar 1 spectrum. 
 
 Figure 4.7 Sugar 1 glycosylation of rProCA1 MALDI analysis using a 5:1 molar ratio.  Left:  MALDI mass spectra of the contrast agent before any sugar modification.  The doublet peak is shown at a molecular weight of 5654.214 Da.  The contrast agent singlet peak was labeled at 11307.549 Da. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 1 modification using a 5:1 molar ratio.  This spectrum exhibits a doublet peak of the contrast agent at 5656.101 Da, as well as an rProCA1 singlet peak at 11310.701 Da.  This spectrum also depicts a peak for the Glyco-rProCA1 with Sugar 1 modification at 12572.599 Da.  The molecular weight of this sugar is 1146.39 Da.  These results are consistent with determining a 1 % successful glycosylation of the contrast agent.  The glycosylated peak is highlighted by a red circle.   
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Sugar 2 was also analyzed in using MALDI mass spectroscopy in Figure 4.8 using 
samples before and after glycosylation of rProCA1 using Sugar 2.  The left image is the MALDI 
spectrum of the contrast agent before modification.  The right image depicts the MALDI 
spectrum of the contrast agent after glycosylation with Sugar 2.  The spectrum on the left is the 
same as the left image in Figure 3.5, the same protein was used for the glycosylation studies 
using the varying sugars, depicting a pure protein with a doublet peak at 5654.214 Da and a 
singlet peak at 11307.549 Da.  The spectrum on the right shows a singlet for the contrast agent at 
11325.554 Da, and a glycosylated peak of the contrast agent at 12102.677 Da.  The difference in 
the labeled Glyco-rProCA1 peak and the labeled rProCA1 peak is 777.123 Da.  This is consistent 
with establishing the successful glycosylation of rProCA1 at 2 % based off the intensities of the 
peaks within the Glyco-rProCA1 MALDI Sugar 2 Zoom spectrum. 
 
 Figure 4.8 Sugar 2 glycosylation of rProCA1 MALDI analysis using a 5:1 molar ratio.  Left:  MALDI mass spectra of the contrast agent before any sugar modification.  The doublet peak is shown at a molecular weight of 5654.214 Da.  The contrast agent singlet peak was labeled at 11307.549 Da. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 2 modification using a 5:1 molar ratio.  This spectrum exhibits a singlet peak of the contrast agent at 11325.554 Da.  This 
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spectrum also depicts a peak for the Glyco-rProCA1 with Sugar 2 modification at 12102.677 Da.  The molecular weight of this sugar is 660.23 Da.  These results are consistent with determining a 2 % successful glycosylation of the contrast agent.  The glycosylated peak is highlighted with a red circle.    Analysis of Sugar 3 glycosylation using MALDI mass spectroscopy is shown in Figure 
4.9.  The left image is again the MALDI spectrum of the contrast agent before modification.  The 
right image depicts the MALDI spectrum of the contrast agent after glycosylation with Sugar 3.  
The spectrum on the left is the same as the left image in Figure 4.7 and 4.8, the same protein was 
used for the glycosylation studies using the varying sugars, depicting a pure protein with a 
doublet peak at 5654.214 Da and a singlet peak at 11307.549 Da.  The spectrum on the right 
shows a singlet for the contrast agent at 11309.255 Da, and a glycosylated peak of the contrast 
agent at 11516.076 Da.  The difference in the labeled Glyco-rProCA1 peak and the labeled 
rProCA1 peak is 206.82 Da.  This is consistent with establishing the successful glycosylation of 
rProCA1 at 1 % based off the intensities of the peaks in the Glyco-rProCA1 MALDI Sugar 3 
Zoom spectrum. 
 
 Figure 4.9 Sugar 3 glycosylation of rProCA1 MALDI analysis using a 5:1 molar ratio.  
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Left:  MALDI mass spectra of the contrast agent before any sugar modification.  The doublet peak is shown at a molecular weight of 5654.214 Da.  The contrast agent singlet peak was labeled at 11307.549 Da. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 3 modification using a 5:1 molar ratio.  The spectrum depicts a singlet peak for the contrast agent without modification at 11309.255 Da, and a singlet peak for the Glyco-rProCA1 with Sugar 3 modification at 11516.076 Da.  The molecular weight of this sugar is 524.15 Da.  These results are consistent with determining a 1 % successful glycosylation of the contrast agent.  The glycosylated peak is highlighted with a red circle.   Sugar 4 glycosylation using MALDI mass spectroscopy is depicted in Figure 4.10.  The 
left image is again the MALDI spectrum of the contrast agent before modification.  The right 
image depicts the MALDI spectrum of the contrast agent after glycosylation with Sugar 4.  The 
spectrum on the left is the same as the left image in Figure 4.7, 4.8, and 4.9, the same protein was 
used for the glycosylation studies using the varying sugars, depicting a pure protein with a 
doublet peak at 5654.214 Da and a singlet peak at 11307.549 Da.  The spectrum on the right 
shows a singlet for the contrast agent at 11450.956 Da, and a glycosylated peak of the contrast 
agent at 12146.150 Da.  The difference in the labeled Glyco-rProCA1 peak and the labeled 
rProCA1 peak is 695.19 Da.  This is consistent with establishing the successful glycosylation of 
rProCA1 at 78 % based off the intensities of the peaks within the Glyco-rProCA1 Sugar 4 
MALDI spectrum. 
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 Figure 4.10 Sugar 4 glycosylation of rProCA1 MALDI analysis using a 50:1 molar ratio.  Left:  MALDI mass spectra of the contrast agent before any sugar modification.  The doublet peak is shown at a molecular weight of 5654.214 Da.  The contrast agent singlet peak was labeled at 11307.549 Da. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 4 modification using a 50:1 molar ratio.  The spectrum depicts a singlet peak for the contrast agent without modification at 11450.956 Da, and a singlet peak for the Glyco-rProCA1 with Sugar 4 modification at 12146.150 Da.  The molecular weight of this sugar is 700.22 Da.  These results are consistent with determining a 78 % successful glycosylation of the contrast agent.  The glycosylated peak is highlighted with a red circle.  
 After evaluating the success of the linkers and chain lengths used in the previous 
glycosylation studies, a new sugar was developed with optimal linker and chain length for 
glycosylating the contrast agent.  It was determined that a smaller sugar would be easier to 
synthesis without the FMOC protective linker for rapid glycosylation studies.  The new Sugar 5 
was synthesized as shown in Figure 4.11 in the top left of this figure.  The contrast agent was 
modified using a 90:1 molar ratio of sugar to protein.  Figure 4.11, bottom left, depicts the SDS-
PAGE electrophoresis gel of this modification.  Lane Three shows a band that is slightly higher 
than Lane One, indicating a higher molecular weight than the contrast agent without 
modification.  Lane Three also exhibits no double band formation as shown in Figure 4.10 in the 
glycosylation of Sugar 4, indicating a full glycosylation resulting in a fully modified protein 
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without a contrast agent lacking modification; however, when evaluating the MALD mass 
spectrum it is determined that a very small amount of contrast agent lacking modification is still 
present at 11299.302 Da as shown in Figure 4.11 on the right.  This image also depicts a doublet 
peak of the Sugar 5 modified rProCA1 at 5862.786 Da and singlet peaks for the modification at 
11723.681 Da, 12148.241 Da, and 12571.960 Da.  Multiple peaks in the MALDI spectrum in 
this manner indicate multiple lysine residues becoming glycosylated.  The difference of each 
peak from left to right are 424.379, 424.56 and 423.179 Da.  These consistent values indeed 
indicate multiple glycosylation sites. 
 
 
Figure 4.11 Sugar 5 glycosylation of rProCA1 Sugar 5 in a 90:1 molar ratio.  Top Left:  Structure of newly developed Sugar 5.  The molecular weight of this sugar is 538.16 Da. Bottom Left:  SDS-PAGE electrophoresis (15%) gel of the modification of rProCA1 using Sugar 5.  The standard is highlighted in red, and the lanes are as read left to right:  Lane One is the contrast agent without modification, Lane Two is the standard, Lane Three is the sample after 
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Sugar 5 modification, and Lane Four is the sample injected into the mouse after concentration to remove any free sugar. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 5 modification using a 90:1 molar ratio.  The spectrum depicts a singlet peak for the contrast agent without modification at 11299.302 Da.  The doublet peak labeled as Glyco-rProCA1 is the doublet of the modified contrast agent with Sugar 5 at 5862.786 Da.  The singlet peaks of the modified contrast agent are circled in red and are as follows:  11723.681 Da, 12148.241 Da, and 12571.960 Da.  The multiple peaks indicate glycosylation of multiple lysine residues on the contrast agent.    A second modification with an increased molar ratio of 100:1 sugar to protein was 
analyzed using the new Sugar 5.  Figure 4.12, left, depicts the SDS-PAGE electrophoresis gel of 
this modification.  Lane Three shows a band that is slightly higher than Lane One, indicating a 
higher molecular weight than the contrast agent without modification.  Lane Three also exhibits 
no double band formation as shown in Figure 4.10 in the glycosylation of Sugar 4, indicating a 
full glycosylation resulting in a fully modified protein without a contrast agent lacking 
modification.  Newly purified protein was used in this study, requiring analysis of the before 
modification sample using MALDI mass spectroscopy.  This is depicted by the middle image in 
Figure 4.12.  This image shows a doublet peak of the contrast agent without modification at 
5415.773 Da, and a singlet peak of the contrast agent is exhibited at 11305.850 Da.  Sugar 5 
modified rProCA1 MALDI analysis is also shown in this figure on the right.  A doublet peak of 
the modified rProCA1 is shown at 6081.278 Da and singlet peaks for the modification at 
11739.628 Da, 12163.860 Da, and 12588.165 Da.  Multiple peaks in the MALDI spectrum in 
this manner continues to indicate multiple lysine residues becoming glycosylated as the 
previously glycosylated sample in Figure 4.11 depicts.  The difference of each peak from left to 
right beginning with the no modification peak in the middle image are 433.778, 424.232 and 
424.305 Da.  These consistent values certainly indicate multiple glycosylation sites giving 
constant results from the previously modified contrast agent using Sugar 5 at a 90:1 molar ratio. 
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Figure 4.12 Modification of rProCA1 with Sugar 5 100:1 molar ratio.  Left:  SDS-PAGE electrophoresis (15%) gel of the modification of rProCA1 using Sugar 5.  The standard is highlighted in red, and the lanes are as read left to right:  Lane One is the contrast agent without modification, Lane Two is the standard, and Lane Three is the sample after Sugar 5 modification at a 100:1 molar ratio of sugar to protein. Middle:  MALDI mass spectra of the contrast agent before any sugar modification.  The doublet peak is shown at a molecular weight of 5415.773 Da.  The contrast agent singlet peak was labeled at 11305.850 Da. Right:  MALDI mass spectra of the glycosylated rProCA1 after Sugar 5 modification using a 100:1 molar ratio.  The doublet peak labeled as Glyco-rProCA1 is the doublet of the modified contrast agent with Sugar 5 at 6081.278 Da.  The singlet peaks of the modified contrast agent are circled in red and are as follows:  11739.628 Da, 12163.860 Da, and 12588.165 Da.  The multiple peaks indicate glycosylation of multiple lysine residues on the contrast agent.   Table 4.1 conclusively outlays all the perimeters that were performed in the glycan 
modification of rProCA1.  In this table, it can be seen that successful glycosylation of rProCA1 
was achieved at the highest level using a 100:1 molar ratio with Sugar 5, which contains a two 
carbohydrate chain length.  The highest number of lysine residues that could be glycosylated are 
three using a 100:1 molar ration of sugar to protein.  Rat ProCA1 contains six lysine residues; 
however, due to the accessibility of the lysine residues as some are on the protein’s surface, and 
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some are hidden inside the structure making them unable to be accessible to glycosylation.  
Future studies will be to probe further into creating a multivalent ideal ligand for ASGPR that is 
trivalent and contains an N-acetylgalactosamine-terminated glycopeptide.  This molecular probe 
must be easy to synthesize and hydrolytically stable. 
 
Table 4.1 Summary of N-glycosylation of rProCA1. 
 
4.3 Conclusions 
In this chapter, we first designed several sugars or glycans with varied linkers and 
carbohydrate chain lengths for the N-glycosylation of rProCA1 to optimize the perimeters and 
yield of modification.  All these reactive sugars were verified and characterized using both 1H 
NMR and 13C NMR.  We have observed that a molar ratio range of 50-90 sugars for one protein 
is required to see any protein modification.  At a ratio from 90 to 100, three lysine residues of 
ProCA1 were modified by lactose with a 2 carbon linker analyzed and confirmed by MALDI 
mass spectroscopy.  This lactose modified rProCA1 contrast agent will be used in Chapter 5 to 
determine in vitro and in vivo application.   
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5 IN VITRO AND IN VIVO STUDIES OF LYSINE MODIFIED PROCA1 
5.1 Introduction 
The focus of this chapter is to characterize the biophysical properties for metal binding, 
relaxivity, and in vivo MR imaging of the glycosylated rProCA1 compared to non-modified 
rProCA1 and PEGylated hProCA1-affi; as well as, inductively coupled plasma-optical emission 
spectrometer (ICP-OES) to detect gadolinium concentration in specific organs to study 
biodistribution of ProCA, and tissue staining to confirm the biodistribution of these contrast 
agents.  Determining metal binding is important in protein engineering ProCA for MRI to 
generate a stronger coordination in the pre-existing binding pocket to improve its gadolinium 
metal binding affinities and selectivity in order to determine toxicity of these contrast agents 
because free gadolinium in the body is toxic.  Relaxivity studies are used to characterize the 
ability of ProCA to utilize these paramagnetic metal ions such as gadolinium and determine if an 
increase the relaxation rate of the surrounding water proton spins per concentration of a contrast 
agent under magnetic field is possible.  MR imaging of ProCA is performed to test the ability of 
ProCA to present the in vivo functioning, and targeting capabilities of lysine modified ProCA1 
compared to the non-modified rProCA1.  ICP-OES aids in the confirmation the bio distribution 
of the lysine modified ProCA1 in various organs by detecting gadolinium.  This is even further 
confirmed by performing immunohistochemistry tissue staining and targeting capabilities of 
these contrast agents are evaluated.  Relaxivity, MR imaging, ICP-OES, and IHC were all 
performed by Dr. Jingjuan Qiao. 
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5.2 Results and Discussion 
5.2.1 Metal Binding Affinity and Relaxivity 
One of the requirements in developing a high quality gadolinium binding contrast agent 
is creating a contrast agent with a high gadolinium binding affinity and a high metal selectivity 
for Gd3+ over physiological metals.  If free gadolinium is released by a contrast agent, the free 
gadolinium will produce a toxic effect called nephrogenic system fibrosis, NSF [34].  If a 
physiological metal binds to the contrast agent by out competing gadolinium, it can hamper the 
imaging development in vivo [61].  Weak binding between Gd3+ and contrast agents leads to 
accumulation of free gadolinium and free contrast agents in the kidney causes lack of proper 
excretion out the body, and inevitably can cause renal failure.  It is important to circumvent any 
issues with gadolinium toxicity by performing Fluo-5N dye competition to determine gadolinium 
metal binding affinity in these lysine modified ProCA. 
Metal binding affinity of gadolinium, Gd3+, with rProCA1, with and without lysine 
modification, contrast agent was determined using the method described in Section 2.2.11.  The 
results are portrayed below in Figure 3.11.  The binding affinity of rProCA1-Gd3+ Glyco-
rProCA1-Gd3+ contrast agents were determined using fluorescent dye, Fluo-5N Pentapotasium 
Salt, which is a weak calcium indicator. The binding affinity of Fluo-5N to Gd3+, 2.6 ×10 -12 has 
been previously determined by Yang’s lab using Fluo-5N-NTA buffer system [40].  The 
experiment was conducted using metal concentration, Gd3+, and dye concentrations of 1 µM and 
10 mM HEPES, pH 7.3.  The initial fluorescence intensity of was measured between 500-650 nm 
with an excitation at 499 nm.  Concentrations of ProCA were titrated into the sample of metal, 
dye, and buffer causing the decrease in fluorescence intensity seen in Figure 5.1 until saturation 
is achieved using three trials.  The change in fluorescence is related to the contrast agents’ ability 
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to out compete the gadolinium bound to the dye.  ProCA do not fluoresce and when the 
gadolinium binds to the contrast agent the intensity decreases.  Figure 5.1 shows the fluorescence 
intensity verses the wavelength within the curve fitting graphs.  The fitted curve at maxima 515 
nm is also depicted in this figure allowing Kapp to be determined and ultimately Kd for rProCA1-
Gd3+ and Glyco-rPrOCA1-Gd3+ by Equation 2-3.  The binding affinity of rProCA1-Gd3+ was 
determined to be 7.77 x 10-13 M using the Fluo-5N competition assay.  The binding affinity of 
Glyco-rPrOCA1-Gd3+ was found to be 9.49 x 10-12 M. 
 
 
Figure 5.1  Fluo-5N dye competition to determine gadolinium metal binding affinity in rProCA1 (left) and Glyco-rProCA1 (right).  The fluorescence spectra of rProCA1 titration using Fluo-5N dye is shown above inside the normalized curve fitting graphs.  Excitation at 499 nm and an emission range of 500-650 nm was used to obtain the data.  The fitted curve at a maximum intensity of 515 nm was used to fit the curve using a dissociation constant of 2.6 × 10−12 M of gadolinium to Fluo-5N dye using competition equation, Equation 2-3.    
Relaxivity determines the ability of these contrast agents to increase the relaxation rates 
of surrounding proton spins as described in Chapter 1.  Optimizing relaxivity will improve 
the contrast of the image and contrast agents can then be used to study tissue specific areas 
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where the contrast agent better diffuses to perform in vivo magnetic resonance imaging.  
The relaxivity of MRI contrast agents depends on the molecular structure and kinetic of the 
complex.  To increase the number of water molecules that are in the inner sphere of the complex, 
or to slow down the molecular rotational correlation time are possibilities to improve the 
water relaxivity.  These studies were performed on each modified version of ProCA1 and non-
modified rProCA1 by Dr. Jingjuan Qiao, and the relaxivity was measured using a 60 MHz 
relaxometer (Bruker).  A high relaxivity that is comparable to or higher than the commercial 
small molecule contrast agents is needed for ProCA to be competitive at clinical setting.   
Relaxivity of Glyco-rProCA1 was determined in accordance with Section 2.2.9.  The 
results from this experiment is displayed in Figure 5.2.  The bar graph in 5.2, left, shows the 
relaxivity measurement comparison of these modifiable ProCA to clinically available MRI 
contrast agents [60].  In this figure, ProCA1-Glyco1 is glycosylated rProCA1 with free sugar in 
the sample and ProCA1-Glyco2 is after free sugar is removed from the sample.  The right image 
in Figure 5.2 is the relaxivity measurements of Glyco-rProCA1 in comparison to ProCA1 with 
no lysine modification and with lysine PEGylated ProCA1, ProCA1-PEG in a table.  After 
removing free sugar the relaxivities of Glyco-rProCA1 was the same in comparison of r1 values 
with rProCA1 without modification.  The r2 value of Glyco-rProCA1 was found to be higher 
than rProCA1 without modification; however, again the r2 value was lower than rProCA1-PEG.  
T1 weighted contrast agents create a brightened image using positive contrast and T2 weighted 
contrast agents create darkened images by using negative contrast.  T1 in this figure is the 
longitudinal relaxation times of the hydrogen water molecules, and T2 is the transverse 
relaxation times.  T1 weighted contrast agents shorten T1 and T2 relaxation time, and T2 
weighted contrast agents have a shorter T2, transverse, relaxation time when compared to T1, 
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longitudinal.  These relaxation times are displayed in the figure for both lysine modified rProCa1 
and rProCA1 without modification.  Glycosylation will aid in shortening these values by 
increasing the rotational correlation time by increasing the molecular size of the contrast agent.  
Glycan reagent also acts a hydrophilic attractant that gathers water molecules closer to the 
contrast agent to increase the water exchange rate.   
 
 
Figure 5.2 Relaxivity comparison of current clinically available contrast agents, ProCA and glycosylation/PEGylation modification of ProCA [60].  Left:  Relaxivity comparision of current clinically available contrast agents using a bar graph to evalute both r1, white bar, and r2, black bar, values of each.  Right:  Table generated to evaluate relaxation times, T1 and T2 values, and relaxivity, r1 and r2, of rProCA1 without modification, with glycosylation modification, and with PEGylation modification.  
5.2.2 Serum Stability 
Serum stability studies were conducted in accordance to Section 2.2.10.  In this study, 
previously obtained human serum was used and described in Figure 5.3 for the studies of 
rProCA1 without lysine modification.  In this figure, the left image shows the serum stability 
over time up to 10 hours.  The rProCA1 band is imaged around 11.2 kDa, while the human 
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serum is imaged as having multiple bands.  The protein contrast agent is shown to be stable up to 
10 hours in this image; however, the left image shows the serum stability up to 6 days.  In this 
image the protein contrast agent is only imaged up to day one.  The second day lane in this image 
shows only a very light band for the protein contrast agent indicating a breakdown of the protein 
in human serum.  Another phenomenon in this image is the breakdown of human serum albumin 
around 66.5 kDa imaged in the lanes for 3 days to 6 days incubation.  This breakdown is as 
expected for human serum albumin and for the no modification rProCA1 contrast agent.  
 
 
Figure 5.3 Human serum stability of rProCA1 without modification.  SDS-PAGE electrophoresis (15%) gels, the standard is highlighted in red. Left:  SDS-PAGE of rProCA1 serum stability over 10 hours, lanes read left to right as follows:  human serum only sample, blank lane, marker, rProCA1 only sample (band for this protein is imaged around 11.2 kDa), rProCA1 and human serum initial sample, rProCA1 and human serum after 2 hours incubation at 37°C, sample taken after 4 hours incubation, sample of 6 hours incubation, 8 hours incubation, and 10 hours. Right:  SDS-PAGE of rProCA1 human serum stability by the day up to 6 days, lanes read left to right as follows:  human serum only sample, blank lane, standard, rProCA1 only sample (band is imaged around 11.2 kDa), sample taken after 1 day incubation of both rProCA1 and serum at 37°C, sample taken after 2 days incubation, sample after 3 days, the sample of 4 day incubation, 5 days incubation, and 6 days.  
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Serum stability studies were also conducted on glycosylated rProCA1 in accordance to 
Section 2.2.10.  In this study, previously obtained human serum was used and described in 
Figure 5.4 for the studies of the Glyco-rProCA1.  In this figure, the left image shows the serum 
stability over time up to 10 hours.  The Glyco-rProCA1 band is imaged around 11.7 kDa, while 
the human serum is imaged as having multiple bands.  The protein contrast agent is shown to be 
stable up to 10 hours in this image on the left and also up to 6 days in the gel on the right.  
Unlike the no modification rProCA1 the image on the right in this figure does not show a 
breakdown of human serum albumin as expected.  This could be due to the free sugar in the 
sample that also has added stability to the serum albumin by glycosylating it during incubation.  
This image clearly shows the increased stability in human serum albumin; as well as, the 
increased stability of rProCA1 with the lysine modification of glycosylation with Sugar 5.  
 
 
Figure 5.4 Human serum stability of Glyco-rProCA1 with Sugar 5 lysine modification.  SDS-PAGE electrophoresis (15%) gels, the standard is highlighted in red. Left:  SDS-PAGE of Glyco-rProCA1 serum stability over 10 hours, lanes read left to right as follows:  human serum only sample, blank lane, marker, Glyco-rProCA1 only sample (band for this protein is imaged around 11.7 kDa), Glyco-rProCA1 and human serum initial sample, 
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Glyco-rProCA1 and human serum after 2 hours incubation at 37°C, sample taken after 4 hours incubation, sample of 6 hours incubation, 8 hours incubation, and 10 hours. Right:  SDS-PAGE of rProCA1 human serum stability by the day up to 6 days, lanes read left to right as follows:  human serum only sample, blank lane, standard, Glyco-rProCA1 only sample (band is imaged around 11.7 kDa), sample taken after 1 day incubation of both Glyco-rProCA1 and serum at 37°C, sample taken after 2 days incubation, sample after 3 days, the sample of 4 day incubation, 5 days incubation, and 6 days.   
5.2.3 In vivo Mouse MRI 
In vivo MR imaging studies were also performed by Dr. Jingjuan Qiao using a 4.7 T 
Varian MRI scanner at Emory University.  Anaesthetized CD1 mice were injected using tail vein 
injection.  As discussed in Chapter 1 MRI enhancement relaxation rates effects MR signal 
intensity.  This is due to Larmor frequency caused by the magnetic moment of the contrast agent.  
These in vivo studies also allow the biodistibution change, targeting capabilities, and tissue 
dispersion of the lysine modified ProCA1 to be determined.  This can then be used in future 
studies at tissue specific regions to determine disease prognosis. 
MRI of rProCA1 without modification was performed and the results of this experiment 
is shown below in Figure 5.5.  In this figure, slight contrast is seen 30 minutes and 3 hours after 
injection of the contrast agent; however, in comparison to lysine modified ProCA1-PEG, which 
is PEGylated ProCA, the intensity of the contrast is drastically increased.  This is depicted in 
Figure 5.6.  Veins and specific organs can be seen much clearer.  This PEGylated ProCA1 is 
cleared through the kidney and uptake of this area highlights the kidney enabling tumor imaging 
capabilities in the kidney.  When glycan modification is performed as in Figure 5.7, ProCA1 
increases the signal intensity.  The Glyco-rProCA1 contrast agent will change biodistribution and 
uptake of the contrast agent can be seen in the liver region, but not in the kidney.  This exciting 
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discovery of Glyco-rProCA1clearance through the liver provides capability of assigning any 
possible tumors in the liver.   
 
 
Figure 5.5 MR images of CD1 mouse before and after tail vein injection of CD1 mice of rProCA1 without lysine modification.  
99 
 
Figure 5.6 MR images of mouse before and after tail vein injection of ProCA1-PEG with lysine modification using PEG.  
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Figure 5.7 MR images of mouse before and after tail vein injection of Glyco-ProCA1 with lysine modification using Sugar 5.  
The comparison of contrast to noise ratio seen in Figure 5.8 clearly summarizes the 
impact of lysine modification on ProCA improving relaxivity in both the liver and kidney 
regions of interest, ROI, for Glyco-rProCA1 and ProCA1-PEG which in turn increases signal 
intensity.  Signal is measured as a mean in the ROI and contrast is found by looking at the 
difference of the signal in two regions.  Contrast to noise ratio is created by differences in the 
signal in the ROI and the noise of interest.  In the Glyco-ProCA1 shows greater uptake in the 
liver three hours after injection rather than the kidney, and ProCA1-PEG shows greater uptake in 
the kidney three hours after injection rather than the liver.  After the contrast agents circulates it 
will then be cleared out these organs.  PEGylation and glycosylation of these contrast agents 
make a more hydrophilic drug which is normally excreted out the kidney [62].  Glyco-rProCA1 
contains not only hydrophilic characteristics, but also a lactose targeting moiety which will but 
taken up by ASGPR in the liver.  This targeting moiety and its interaction with ASGPR is 
pertinent for excretion out the liver rather than the kidney region. 
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Figure 5.8 MRI contrast change comparison of lysine modified ProCA1.  Left:  Glyco-ProCA1 modified contrast agent shows an increase in liver contrast that is greater than the kidney contrast three hours after injection of this contrast agent. Right:  ProCA1-PEG modified contrast agent shows an increase in kidney contrast greater than liver contrast three hours after injection of the contrast agent.  
 Figure 5.9 shows a three hour comparision three hours after injection of each contrast 
agent discussed in this chapter.  Rat ProCA1 without modification (left) shows little contrast, 
with uptake in the kidney region (blue circle).  Glycoyslated ProCA1 (middle) shows high 
contrast with uptake of this contrast agent in both the liver (red circle), kidney (blue circle), and 
salivary gland regions (green circle).  PEGylated ProCA1 shows little contrast in the liver (red 
circle) and high contrast uptake in the kidney.  As discussed previously a hydrophilic drug will 
excrete out the kidneys; however, Glyco-ProCA1 contains an ASGPR targeting moiety which 
will be taken up in the liver region.  Mucous secretory glands contain mucin and glycoconjugates 
which could uptake the lactose sugar moeity covalently bonded onto ProCA [63]. 
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Figure 5.9 Three hour after injection comparison of rProCA1 without modification (left), Glyco-ProCA1 (middle), and PEG-ProCA1 (right).  
5.2.4 Biodistribution and Histology Analysis 
ICP-OES and immunohistochemistry, IHC, staining is both performed after MRI to 
evaluate distribution of ProCA in tissue.  ICP-OES can be used to detect gadolinium 
concentration in specific organs.  This is an analytical technique that excites atoms and ions to 
detect emission at wavelengths that are specific to an element.  The detection of gadolinium in 
organs will aid in determining the distribution of lysine modified and non-modified ProCA1.  
Mouse tissue is melted in 70 % nitric acid overnight until completely dissolved and then diluted 
in 2 % nitric acid.  The sample is filtered using a 0.22 µm membrane with a volume of 4-5 mL to 
measurement using ICP-OES (Agilent Technology).  The results of this are shown in Table 5.1.  
This table makes it clear that kidney uptake of contrast agent ProCA1-PEG (ProCA1-affi-P40) 
was detected by ICP-OES detection of gadolinium confirming the distribution of this contrast 
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agent to the kidney, while Glyco-ProCA1 (ProCA1-Glyco) shows an uptake in the liver in order 
to confirm the biodistribution to the liver.  It is interesting to note the uptake of the contrast 
agents in other regions of the body indicative of a possible whole body imaging capability to aid 
in the detection of targeted carcinomas using either contrast agent. 
 
Table 5.1 Gadolinum concentration of primary organs after MRI by ICP-OES.  Units of measurement are in (parts per billion/gram/dose). 
 
 
IHC tissue staining will also help in confirming the targeting capabilities of these contrast 
agents and the biodistribution change.  Tissue of primary organs are dissected out and frozen 
sections are made using liquid nitrogen.  These frozen samples are sliced and then stained using 
immunofluorescent staining highlighting accumulation of the ProCA, red for ProCA1-PEG and 
green for Glyco-ProCA1 using a fluorescently labeled secondary antibody.  The tissue samples 
are also stained using 4',6-diamidino-2-phenylindole, DAPI, which binds to the A-T regions of 
DNA effectively staining the nucleus of the tissue cells blue.  The fluorescence is the detected 
and imaged using a Zeiss microscope; these results are depicted in Figure 5.10.  The 
biodisribution pattern of lysine modified ProCA1 shows variation in both mouse liver and 
kidney.  The top left panel indicates Glyco-ProCA1 stains liver sinusoid which leaves spaces in 
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between.  This is indicative of targeting capabilities of this lysine modified ProCA to distribute 
specifically around liver cells.  The top middle panel of PEG-ProCA1 shows a homogeneous 
distribution which does not indicate targeting capability in the liver by this lysine modified 
ProCA.  The distributions of Glyco-ProCA1 and PEG-ProCA1 in kidneys are similar.   
 
 
Figure 5.10 Immunohistochemistry staining of lysine modified ProCA1 in the kidney and liver.  
5.3 Conclusion and Future Work 
In this chapter, the characterization of the biophysical properties for metal binding, 
relaxivity, and in vivo MR imaging of the glycosylated rProCA1 compared to non-modified 
rProCA1 and PEGylated hProCA1-affi; as well as, inductively coupled plasma-optical emission 
spectrometer (ICP-OES) to detect gadolinium concentration in specific organs to study 
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biodistribution of ProCA, and tissue staining to confirm the biodistribution of these contrast 
agents were determined.   
Metal binding affinities of gadolinium for both glycan modified rProCA1 and non-
modified rProCA1 were found to be 9.49 x 10-12 M and 7.77 x 10-13 M respectively using the 
Fluo-5N competition assay.  This number is comparable to previously published data on 
rProCA1 without modification which found the metal binding to gadolinium to be 7.0 x 10-13 M 
and it is also comparable to the humanized ProCA-affi with PEG lysine modification which 
found gadolinium metal binding to be 1.86 x 10-12 M [28, 40].   
Relaxivity and serum stability studies were also conducted on these modifiable ProCA.  
ProCA1 has in both r1 and r2 values that are higher in comparison to clinically available contrast 
agents.  After removing free sugar, it can be seen that the relativities of Glyco-rProCA1 was the 
same in comparison of r1 values with ProCA1 without modification.  The r2 value of Glyco-
rProCA1 was found to be higher than ProCA1 without modification; however, again the r2 value 
was lower than ProCA1-PEG.  Serum stability studies found that an increased stability of 
rProCA1 is obtained upon the lysine modification of glycosylation with Sugar 5.  Serum albumin 
was also found to be stabilized in this section.  This could be due to the free sugar in the sample 
that also has added stability to the serum albumin by glycosylating it during incubation.  The 
stability of Glyco-rProCA1 demonstrates a strong thermo-stability, high solubility, and resistance 
to protease cleavage provided by the N-glycosylation using lactose.  These results are consistent 
with ProCA1-PEG, indicating that glycosylation is an attractive alternative to PEGylation 
modification. 
We have achieved significant liver MRI enhancement via tail vein injection of Glyco-
rProCA1 with liver enhancement due to high ASGPR expression in the liver.  The liver 
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enhancement by Glyco-rProCA1 is significantly higher than ProCA1-PEG, three hours post 
injection, which proved its strong targeting capability to ASGPR in liver with good penetration. 
This result demonstrated our unique capability in monitoring glycan-lectin interaction in live 
animals by MRI that has never been achieved before.  Glyco-rProCA was found to have greater 
liver enhancement than the kidney at three hours.  It is important to note that previous in vivo 
MR imaging using lactose functionalized magnetoliposomes were developed and were found to 
have hepatocyte targeting to potential aid in the diagnosis of hepatic disease; however, this was 
severely limited by non-specific uptake by kupffer cells [64].  Kupffer cell uptake of 
nanoparticles is such a limitation that a signal intensity change using MRI was not observed.  
This is why it was critical to develop an ASGPR targeted contrast agent using N-glycosylated 
ProCA in order to determine in vivo disease prognosis of hepatic disease to provide an 
alternative to nanoparticle contrast agents for MRI.  This study provides the first in vivo imaging 
that provides both T1 (bright) and T2 (dark) in the liver with a dramatic change in contrast using 
a single gadolinium binding pocket.  The utilization of the single binding pocket lowers possible 
metal toxicity to patients due to the low metal content being injected.  Future studies will 
determine histology of the glandular uptake of Glyco-ProCA1. 
ASGPR targeting capability was evaluated using ICP-OES and IHC staining in order to 
better understand the biodistribution change of modified ProCA.  ProCA1 shows different 
distribution pattern in both mouse liver and kidney.  Glyco-ProCA1 was found to stain liver 
sinusoid which leaves spaces in between; while, ProCA1-PEG shows a more homogeneous 
distribution with the distribution of both Glyco-rProCA1 and ProCA1-PEG in the kidneys to be 
similar.  ICP-OES results also show different distribution patterns by analyzing the gadolinium 
concentration in organs.  Glyco-rProCA1 and ProCA1-PEG show longer circulation time than 
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ProCA1 without modification.  It was found that after 48 hours, the injected reagent, ProCA1-
PEG, shows significantly higher concentration in kidney than Glyco-rProCA1.  Confirming the 
biodistribution of these contrast agents.   
In order to confirm the binding of Glyco-rProCA1 to ASGPR more cell imaging will be 
used in the future to determine the quantifiable binding capacity of these modified ProCA to 
ASGPR.  Optimized improvements on the sugar moiety for more specific binding moieties for 
ASGPR can be utilized by replacing lactose for GalNAc with an ASGPR affinity of 40.4 ± 9.5 
µM, or with a trifluoromethyl acetamide modification to GalNAc, with ASGPR affinity of 1.2 ± 
0.4 µM, and another modification for specificity will be provided by adding a linker for trivalent 
binding [56].  This modification would be needed because the native ligands for ASGPR were 
found to bind with low affinity including GalNAc (40.4 ± 9.5 µM), Me-Gal (880 ± 200 µM), and 
lactose (257 ± 23 µM).   
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6 OVER ALL CONCLUSION AND SIGNIFICANCE OF THIS WORK 
MRI is a powerful diagnostic tool that is non-invasive with deep tissue penetration.  MRI 
can provide detailed information about tissues and organs without utilizing any harmful 
radiations.  Due to low sensitivity, contrast agents are largely used to enhance MRI images.  In 
the past decade, Dr. Jenny Yang’s lab has adopted and merged the idea of MRI contrast agents 
with their excellent knowledge of protein chemistry and developed novel class of Protein based 
MRI contrast agents.  ProCAs can not only improve the low sensitivity with their dramatic 
contrasting ability but also target the specific cancer biomarkers for early detection of cancerous 
tissues using MRI.  First generation of ProCA was developed by constructing a Gd3+ binding site 
on a stable scaffold protein, domain 1 of rat CD2.  ProCA1 demonstrated ten times higher 
relaxivities as compared to the clinically used MRI contrast agent.  High relaxivity directly 
corresponds to the use to low dosage, and low toxicity.  Furthermore, targeted ProCA1 has 
proven to be excellent molecular imaging probe against breast cancer.   
Chapter 3 describes two generations of ProCA that were expressed and purified, as well 
as, the humanization of first generation ProCA.  In order to improve the thermostability, select a 
thermodynamically stable scaffold protein, and modify metal binding by having additional 
binding sites to optimize readout, a series of third generation of ProCAs, ProCA3 were designed 
by Dr. Shenghui Xue.  During this process, a series of ProCAs were developed with even more 
improved in vivo properties.  A new scaffold protein parvalbumin was selected due to many 
advantages associated with its physical and functional properties.  Both generations of ProCA, 
ProCA1 and ProCA32 have various benefits and drawbacks to their utilization as contrast agents 
for MRI.  ProCA1 and ProCA32 have capabilities of being utilized as a targeting contrast agent 
by grafting an affibody onto the contrast agents.  These contrast agents also have been to be 
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modified using lysine modification to improve r1 and r2 relaxivities, improvement in in vivo dose 
efficiency, reduced immunogenicity, and an increase in solubility.  ProCA32 has been optimized 
further using a cysteine site specific PEGylation modification in order to develop a 
homogenously modified protein.  ProCA1 contains many lysine residues and cannot be 
homogenously modified using this method; however, this is an important development in order 
to push into the clinical arena.  ProCA32 has demonstrated strong Gd3+ binding affinity with Kd 
of 10-22 M, while ProCA1 only demonstrates Gd3+ binding affinity with Kd of 10-12 M [29].  This 
could be due to the natural metal binding capability of the scaffold parvalbumin.  ProCA32 also 
exhibits high relaxivity due to the two metal binding pockets to increase pay load in comparison 
to ProCA1.  Rat and humanized first generation and humanized third generation ProCA were 
expressed and purified with a yield of 6.11, 3.01, and 9.04 mg/L respectively.   
Continuous research into cancer biomarkers provides and avenue for evaluation and 
diagnosis of disease development and detection.  Lectins and glycans are important biomarkers 
for disease diagnosis, progression, and drug treatment.  We have to probe further into this to see 
if there is an affinity ligand like lactose that can be used to target disease biomarkers like lectins 
and detect it using imaging methodologies for disease diagnosis via ASGP receptor.  In Chapter 
4, the N-glycosylation of rProCA1 was performed in order to optimize the perimeters, linkers, 
and chain length with sugars synthesized and characterized in order to develop a glycan probe 
for targeting ASGPR.  It was found that successful glycosylation of rProCA1 was achieved at the 
highest level using a 100:1 molar ratio with Sugar 5, which contains a two carbohydrate chain 
length.  The highest number of lysine residues that could be glycosylated are three using a 100:1 
molar ration of sugar to protein.  Future studies will be to probe further into creating a 
multivalent ideal ligand for ASGPR that is trivalent and contains an N-acetylgalactosamine-
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terminated glycopeptide.  This molecular probe must be easy to synthesize and hydrolytically 
stable. 
In Chapter 5, the characterization of the biophysical properties for metal binding, 
relaxivity, and in vivo MR imaging of the glycosylated rProCA1 compared to non-modified 
rProCA1 and PEGylated hProCA1-affi; as well as, inductively coupled plasma-optical emission 
spectrometer (ICP-OES) to detect gadolinium concentration in specific organs to study 
biodistribution of ProCA, and tissue staining to confirm the biodistribution of these contrast 
agents.  Metal binding affinities of gadolinium for both glycan modified rProCA1 and non-
modified rProCA1 were found to be 9.49 x 10-12 M and 7.77 x 10-13 M respectively using the 
Fluo-5N competition assay.  This number is comparable to previously published data on 
rProCA1 without modification which found the metal binding to gadolinium to be 7.0 x 10-13 M 
and it is also comparable to the humanized ProCA-affi with PEG lysine modification which 
found gadolinium metal binding to be 1.86 x 10-12 M [28, 40].  ProCA1 has in both r1 and r2 
values that are higher in comparison to clinically available contrast agents.  After removing free 
sugar it can be seen that the relativities of Glyco-rProCA1 was the same in comparison of r1 
values with ProCA1 without modification.  The r2 value of Glyco-rProCA1 was found to be 
higher than ProCA1 without modification; however, again the r2 value was lower than ProCA1-
PEG.  Serum stability studies found that an increased stability of rProCA1 is obtained upon the 
lysine modification of glycosylation with Sugar 5.  The liver enhancement by Glyco-rProCA1 is 
significantly higher than ProCA1-PEG, three hours post injection, which proved its strong 
targeting capability to ASGPR in liver. This result demonstrated our unique capability in 
monitoring glycan-lectin interaction in live animals by MRI that has never been achieved before.  
Glyco-rProCA was found to have greater liver enhancement than the kidney at three hours.  
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ProCA1 shows different distribution pattern in both mouse liver and kidney.  Glyco-ProCA1 was 
found to stain liver sinusoid which leaves spaces in between; while, ProCA1-PEG shows a more 
homogeneous distribution with the distribution of both Glyco-rProCA1 and ProCA1-PEG in the 
kidneys to be similar.  ICP-OES results also show different distribution patterns by analyzing the 
gadolinium concentration in organs.  Glyco-rProCA1 and ProCA1-PEG show longer circulation 
time than ProCA1 without modification.  It was found that after 48 hours, the injected reagent, 
ProCA1-PEG, shows significantly higher concentration in kidney than Glyco-rProCA1. 
These major findings support the N-glycosylation functional stability, increase in 
circulation half-life, decreased degradation by metabolic enzymes, and increase in protein 
stability making N-glycosylation modification to ProCA1 an attractive alternative to lysine 
PEGylation.  It was also found that glycan modification will also provide an added benefit of 
biomarker targeting to ASGPR in the liver allowing for a change of biodistribution of ProCA 
with excretion out the liver, whereas, previous PEGylation modification to this contrast agent 
provided renal excretion out the kidneys.  This targeting moiety can be further optimized by the 
tailoring of a hydrolytically stable and easily synthesized molecular probe for ASGPR that is N-
acetylgalactosamine-terminated glycopeptide and covalently modify ProCA to determine this 
newly modified ProCA relaxivity, metal binding affinity, biodistribution, and specific lectin 
targeting capability both in mice in vivo and in vitro.  Another future avenue to explore is the 
possibility of whole-body imaging using a non-specific glycan to determine if whole-body 
contrast is possible without harmful radiation, low cost, and high contrast resolution. 
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Appendix A.1 Mass Spectroscopy MALDI Full Spectrums 
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Appendix B 
For full data set of metal binding, ICP-OES, MRI raw data, and letters of permission 
please see http://ppl.ug/agWhhJXJ_Yo/. 
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